




EX VIVO  
LUNG PERFUSION  
p. 8



PULMONARY  
THROMBOENDAR-  
TERECTOMY FOR  
CTEPH  
p. 16



MANAGING  
PRIMARY  
IMMUNODEFICIENCIES  
p. 23



# RespiratoryExchange


Research and News for Physicians from Cleveland Clinic's Respiratory Institute

Winter | 2017

FEATURE

**Pathobiological  
Links Discovered  
Between Asthma  
and Metabolism**

p. 3



## Dear Colleagues:

Welcome to this issue of *Respiratory Exchange*, which highlights the latest discoveries and innovations of our pulmonary, critical care, allergy and clinical immunology staff within Cleveland Clinic's Respiratory Institute.

This issue is particularly representative of the wide range of interests and expertise of the staff in our institute. In these pages, you'll find:

- Details about the discovery of pathobiological links between asthma and metabolism, and key facts about our Asthma Center (pp. 3-5)
- New insights into the mechanosensing pathway involved in idiopathic pulmonary fibrosis (pp. 6-7)
- Highlights of ex vivo lung perfusion and its impact on lung transplantation (pp. 8-10)
- Surprising findings regarding cumulative radiation exposure in the MICU (pp. 11-12)
- A summary of ongoing progress in our Alpha-1 Antitrypsin Center (pp. 13-14)
- A glimpse into our standardization of respiratory therapy across the entire Cleveland Clinic health system (p. 15)
- An overview of the difficult procedure of pulmonary thromboendarterectomy and its success rates in CTEPH (pp. 16-17)
- An introduction to innovative obstructive sleep apnea treatment through hypoglossal nerve stimulation (pp. 18-20)
- A rubric for teaching mechanical ventilation to trainees (pp. 21-22)
- A case highlighting the work of our Adult Immunodeficiency Clinic (pp. 23-24)

We hope you enjoy the articles in this issue of *Respiratory Exchange* and find something useful for your patients, practice, trainees or research. Inside, you'll also find a listing of our actively enrolling clinical trials as well as a comprehensive directory of our staff and their specialty areas. Visit [clevelandclinic.org/pulmonary](http://clevelandclinic.org/pulmonary) to learn more about our clinical research activities.

If you have questions or would like to refer a patient, call our toll-free number for physicians, 866.CCF.LUNG. We welcome your thoughts, feedback and questions.

Sincerely,

Herbert P. Wiedemann, MD, MBA

CHAIRMAN | CLEVELAND CLINIC RESPIRATORY INSTITUTE

### Respiratory Exchange

Robert Kotloff, MD  
Herbert P. Wiedemann, MD, MBA  
Medical Editors

Jackie Riggle  
Marketing Manager

Deborah Booth Summers  
Managing Editor

Barbara Ludwig Coleman  
Art Director

*Respiratory Exchange* is written for physicians and should be relied on for medical education purposes only. It does not provide a complete overview of the topics covered and should not replace the independent judgment of a physician about the appropriateness or risks of a procedure for a given patient.

© 2016 The Cleveland Clinic Foundation  
16-PUL-1263



# Pathobiological Links Discovered Between Asthma and Metabolism

## Asthma: an arginine-driven metabolic disorder

By Weiling Xu, MD, and Serpil Erzurum, MD

Clinicians and researchers have long observed a relationship between asthma and obesity, but the nature of the association has been poorly understood. Our recent research sheds light on this perplexing and important relationship and helps define the role of metabolism in the pathobiology of asthma.


A growing understanding over the past decade is that underlying metabolism contributes in a major way to predisposition to disease, including lung disease. It turns out that your grandmother's adage "You are what you eat" may be true.

### MITOCHONDRIA OF PEOPLE WITH ASTHMA ARE LESS RELIANT ON GLYCOLYSIS


We now recognize that nutritional intake, body fat type and the microbiome can all impact asthma risk and control. Epidemiological studies show a very strong link between asthma and obesity, but causality is not yet established. Plenty of lean people have asthma, and many people with obesity do not.

Our multisite team has been working for the past seven years to elucidate the asthma-metabolism link. In collaboration with Sruti Shiva, PhD, at the University of Pittsburgh, we began our research by studying mitochondrial function in platelets of asthmatic individuals compared with those of healthy individuals.<sup>1</sup> Mitochondria of asthmatics exhibited decreased reliance on glycolysis and greater tricarboxylic acid cycle (TCA) activity, suggesting that oxidative phosphorylation is more efficient in asthmatic individuals (Figure 1).

*Mitochondria of asthmatics exhibited decreased reliance on glycolysis and greater TCA activity, suggesting that oxidative phosphorylation is more efficient in asthmatic individuals.*



**Figure 1:** A: Ultrastructure of mitochondria in asthma airway epithelium. N, nucleus. B: Close-up of A. C: Close-up of B. Different mitochondria are shown by arrowheads. All scale bars: 1 μm.



**Figure 2:** Arginine metabolism and bioenergetics in asthma. A: Inducible nitric oxide synthase (iNOS) converts arginine to citrulline and nitric oxide (NO). Arginase 2 (ARG2), found in mitochondria, converts arginine to ornithine, which is converted to glutamate by ornithine aminotransferase (OAT).  $\alpha$ -ketoglutarate ( $\alpha$ KG) then enters the tricarboxylic acid (TCA) cycle for electron transport chain (ETC) to generate ATP energy. The TCA cycle in mitochondria is linked to the citrulline-NO cycle in the cytosol. B: Greater ARG2 expression (as demonstrated by brown staining on immunohistochemistry) is found in asthmatic bronchial epithelium. Scale bar: 40  $\mu$ m.

**References:**  
 1. Xu W, Cardenes N, Corey C, Erzurum SC, Shiva S. Platelets from asthmatic individuals show less reliance on glycolysis. *PLoS One*. 2015;10(7):e0132007.  
 2. Xu W, Ghosh S, Comhair SA, Asosingh K, Janocha AJ, Mavrakis DA, Bennett CD, Gruca LL, Graham BB, Queisser KA, Kao CC, Wedes SH, Petrich JM, Tuder RM, Kalhan SC, Erzurum SC. Increased mitochondrial arginine metabolism supports bioenergetics in asthma. *J Clin Invest*. 2016;126(7):2465-2481.

Our most recent study of the mechanisms underlying the changes in mitochondrial metabolism revealed that these alterations may be the result of increased expression of type II arginase (ARG2). ARG2 is localized within mitochondria and serves to break down arginine to ornithine, which through several transamination reactions can form  $\alpha$ -ketoglutarate and enter the TCA cycle. The findings showed that the greater levels of mitochondrial ARG2 and arginine flux in asthma accelerate the TCA cycle and cellular respiration (Figure 2).

Interestingly, the ARG2 gene variants lie within an asthma linkage region on chromosome 14q24, and these were some of the earliest and most consistent single nucleotide polymorphisms discovered in genomewide association studies of asthma. In fact, alterations in the ARG2 gene are strongly linked to asthma and asthma severity. In our recent mechanistic studies, mice genetically deficient in ARG2 had alterations in cellular metabolism and more severe asthma inflammation. These studies and prior work indicate asthma is endotypically an arginine-driven metabolic disorder.

**NEXT QUESTIONS — NEW MANAGEMENT FOR ASTHMA?**

Our discoveries open new lines of speculation. All studies were performed in lean individuals, so we do not yet know if metabolic effects differ between individuals with asthma with or without obesity. Drugs that modify mitochondrial bioenergetics are in development but are untested in asthma. Further work is needed to understand whether and how mitochondrial-targeted therapies and/or diet might impact metabolism and control of asthma.



Dr. Xu, Assistant Professor of Pathobiology at the Lerner Research Institute, can be reached at [xuw@ccf.org](mailto:xuw@ccf.org) or 216.445.6625.



Dr. Erzurum, Alfred Lerner Chair of the Lerner Research Institute and staff in Pulmonary Medicine, can be reached at [erzurum@ccf.org](mailto:erzurum@ccf.org) or 216.444.5724.

## Cleveland Clinic Asthma Center

At Cleveland Clinic Asthma Center, experts in Pulmonary Medicine and Allergy and Immunology offer advanced diagnostic testing and innovative treatments for adults with asthma. For those with coexisting conditions, we also coordinate care with many other specialties. In addition to general asthma care, we offer the following specialized programs:

**Care for severe asthma** includes patients who require multiple medications or oral steroids to remain controlled; have high-risk asthma that has resulted in lost days of school or work, or hospitalizations; or are disabled from symptoms or adverse effects of medications. Our protocol explores personalized asthma endotypes; pathobiology of disease is considered when a management plan is initiated. Therapies offered include biologic treatments, aspirin desensitization and bronchial thermoplasty.


In addition to these clinical activities, members of the Asthma Center are involved in a wide array of basic, translational and clinical research projects:

**Programmatic research** funded by the National Heart, Lung, and Blood Institute (NHLBI) aims to uncover the primary causes of asthma and the pathobiology of severe asthma. Special areas of study include gender effects on asthma severity, obesity and diet in airway inflammation, epithelial and T-cell mediators in asthma origins, and the role of extracellular pathologic remodeling of the airway mucosa.

**Asthma care and public health advocacy for community patients** Our efforts include advocacy around air quality, access to care and medications; coordinating and reducing barriers to care for patients presenting to the emergency department who are at highest risk from their asthma; using technologies such as electronic registries and telemedicine to aid access; and monitoring quality metrics regarding the identification of at-risk patients and management of asthma.

**Chronic Cough Clinic** This collaborative effort involving staff from pulmonary medicine, otorhinolaryngology and gastroenterology provides a multidisciplinary approach to the evaluation and treatment of chronic cough.

**Exercise-induced dyspnea in high-performing athletes** Our program provides evaluation for and treatment of various causes for exercise limitation among elite athletes, including occult upper airway abnormalities and pulmonary vascular, cardiac or gastrointestinal conditions. Assessment and care is coordinated among a multidisciplinary team representing pulmonary medicine, cardiology, otorhinolaryngology, gastroenterology and speech therapy.



**NHLBI-funded translational programs** are developing novel diagnostics and predictive testing for asthma phenotypes, with the goal of identifying molecular signatures of types of asthma so that precision therapies can be applied, in particular for the severe unremitting asthma phenotype.

**Longitudinal studies of asthma** in the NHLBI Severe Asthma Research Program (SARP) provide information about the natural history of severe asthma and how biomarkers may identify asthma exacerbations over time.

**Epidemiologic studies of asthma** populations at Cleveland Clinic and in national databases investigate the intrinsic and environmental factors in asthma control and exacerbations.

**To refer a patient, please call 216.444.0582 and ask to be directed to the Asthma Center.**

## Novel Assay Suggests Mechanosensing Pathway Involved in Idiopathic Pulmonary Fibrosis

Olman lab discovers new mechanisms underlying pulmonary fibrosis

Brian D. Southern, MD

Fibrotic disorders such as idiopathic pulmonary fibrosis (IPF) result in progressive scarring and organ dysfunction. In IPF, persistent activation and accumulation of fibroblasts result in excessive connective tissue accumulation and tissue contraction that makes the lung increasingly “stiffer.” This increased tissue stiffness serves as a signal for recruitment and activation of more fibroblasts in a feed-forward fashion that perpetuates the fibroproliferative cycle.

A recently published study from the Olman lab at Cleveland Clinic’s Lerner Research Institute offers glimpses into this cycle that may one day produce novel therapeutic agents for patients with IPF.

### NOVEL ASSAY = NEW INSIGHTS

Much of the research on fibroblast activation in IPF has been performed using plastic or glass tissue culture assay systems that are 1 million orders of magnitude stiffer than actual lung tissue, and may not provide an accurate representation of in vivo fibroblast behavior. In our recent work, we characterize a novel assay system that more closely mimics the natural lung environment of the fibroblast by using actual normal and fibrotic lung tissue.<sup>1</sup>

Briefly, fluorescently labeled human lung fibroblasts were allowed to adhere to normal or fibrotic mouse lung tissue sections. Time-lapse video microscopy was then performed and migratory characteristics were analyzed in fibroblasts attached to normal lung, and compared with those on fibrotic lung. Fibroblasts were also allowed to adhere to the lung tissue sections for 24 to 48 hours, and various markers of myofibroblast differentiation were analyzed. Finally, these

assays were performed in the presence of various inhibitors or stimulators to determine whether the responses were different in fibroblasts on normal versus fibrotic lung.

With this system, we identified for the first time that normal lung stimulates migration of fibroblasts, while fibrotic lung stimulates myofibroblast differentiation. We also demonstrated how these two different responses (migration and myofibroblast differentiation) are both mediated through the molecular motor myosin II. Depending on whether the fibroblast interacts with normal or fibrotic lung, myosin II is activated in a way that either results in migration or myofibroblast differentiation (Figure 1).

### FOCUS ON MYOSIN II: A PARADIGM SHIFT

The multiple, redundant and overlapping pathways in fibrotic disease have been well-established. A heterogeneous population of patients suffers from IPF, and ample evidence demonstrates that the mechanisms underlying the development of fibrosis may vary between patients.

One of the biggest disappointments in the field of IPF has been the number of clinical trials demonstrating either no efficacy or actual harm with the investigated therapies. Many of these trials tended to focus on individual, soluble mediators or isolated pathways known to play a role in fibrosis. Identifying a potential therapeutic strategy that targets a molecule, such as myosin II, that is downstream and common to multiple fibrosis pathways could represent a significant paradigm shift in the treatment of patients with IPF and other fibrotic disorders.

### TRPV4 MEDIATES MECHANOSENSING SIGNAL IN FIBROBLASTS

Previous work from our lab demonstrated for the first time that the mechanosensing signal in fibroblasts is mediated by the transient receptor potential vanilloid 4 (TRPV4) channel.<sup>2</sup> In this work, we showed that the TRPV4 signal converges on this same myosin II protein in fibroblasts (Figure 2). Our data suggest that, in patients with IPF, TRPV4 channel activity and its biological effects are upregulated in lung fibroblasts (Figure 3).

Together, these studies suggest that the fibroblast senses increases in tissue stiffness through TRPV4 and translates those increases into the activation of myosin II in a way that creates a “profibrotic” fibroblast. Our future work will explore the possibility of a dysregulated myosin II pathway in fibroblasts from IPF patients, and whether manipulation of this fibrotic lung-driven pathway could lead to novel therapeutic agents for the devastating disorder of IPF.

### References

1. Southern BD, Grove LM, Rahaman SO, et al. Matrix-driven myosin II mediates the pro-fibrotic fibroblast phenotype. *J Biol Chem.* 2016;291(12):6083-6095.
2. Rahaman SO, Grove LM, Paruchuri S, Southern BD, et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. *J Clin Invest.* 2014;124(12):5225-5238.



Dr. Southern, staff in the Respiratory Institute and Assistant Professor of Molecular Medicine at Cleveland Clinic Lerner College of Medicine,

can be reached at [southeb@ccf.org](mailto:southeb@ccf.org) or 216.444.7655.




Figure 1: Effect of normal versus fibrotic lung on fibroblast phenotype. The consequence of myosin II activation differs depending on whether a fibroblast is interacting with normal or fibrotic lung extracellular matrix. In normal lung, myosin II activation drives highly directional, polarized migration. In fibrotic lung, myosin II activation results in myofibroblast differentiation. The result is migration of fibroblasts from normal to fibrotic lung, where myofibroblast differentiation is enhanced.

All figures and legends republished from reference 1 (Southern et al.) with permission from The American Society for Biochemistry and Molecular Biology.




Figure 2: Inhibition of TRPV4 channel activity abrogates myosin II activation. Immunoblots of cell lysates for activated myosin II (p-MLC2) and total myosin II (MLC2). TGFβ1 (transforming growth factor-beta), a stimulator of myofibroblast differentiation, induced activation of MLC2 maximally from six to 24 hours. When fibroblasts were pretreated with AB1, an inhibitor of TRPV4, myosin II activation was blocked.




Figure 3: Schematic model showing the mechanistic pathway by which TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis. Our data suggest that TRPV4-dependent calcium (Ca<sup>2+</sup>) influx activity is sensitized by stiff matrices within the pathophysiological range. Interaction between TRPV4 activity (Ca<sup>2+</sup> influx) and the profibrotic transforming growth factor-beta 1 (TGFβ1) signals promotes nuclear localization of α-SMA transcription factor, myocardin-related transcription factor A (MRTF-A), via regulation of actomyosin remodeling to potentiate myofibroblast differentiation during fibrogenesis.

## Increasing Transplantable Donor Lungs Through Ex Vivo Lung Perfusion

### Transforming dysfunctional lungs into transplantable ones

By Toshihiro Okamoto, MD, PhD, and Kenneth R. McCurry, MD

Cold storage of donor organs following procurement and prior to transplant decreases metabolic demand and consumption of energy and has been the standard in transplantation for more than 40 years. Severe damage occurs when energy stores are depleted, including increased oxidative stress, inactivation of the sodium pump, cell death and the release of proinflammatory cytokines. Additionally, following implantation, lungs frequently demonstrate varying degrees of ischemia reperfusion injury (IRI), resulting in postoperative graft dysfunction and complications that have short- and long-term implications. Thus, lung preservation and mitigation of IRI remain two of the main concerns in clinical lung transplantation.

#### PREVENTING COLD INJURY WITH EX VIVO


Normothermic ex vivo organ perfusion is based on the rationale that providing oxygen and nutrition at physiologic temperatures on an ex vivo perfusion circuit prior to transplantation can prevent cold injury. Furthermore, it is possible that such ex vivo lung perfusion (EVLP)

could be used to recondition and repair dysfunctional lungs after procurement, thus making them transplantable and resulting in an increased number of lungs available for transplantation.


EVLP could prove especially beneficial when untransplantable, dysfunctional donor lungs have pulmonary edema or areas that remain atelectatic despite in situ recruitment. In EVLP, the high oncotic pressure of the perfusate draws water from the lung tissue and alveoli into the extrapulmonary space, reducing pulmonary edema. Atelectasis can be eliminated through strategic ventilation techniques, which include recruitment maneuvers while on EVLP. Importantly, evaluation of donor lung function is possible during EVLP, allowing ongoing assessment of lung function in response to therapeutic maneuvers.

#### MEETING DEMAND THROUGH RECONDITIONING

In the U.S., 1,600-1,800 lung transplants are performed annually,



► **Figure 1:** Ex vivo lung perfusion system in the McCurry lab.



► **Figure 2:** The relationship between  $\text{PaO}_2/\text{FiO}_2$  (P/F) ratio at  $\text{FiO}_2$  of 0.21 and P/F ratio at  $\text{FiO}_2$  of 1.0 in porcine model. Left: P/F ratio at 3  $\text{FiO}_2$  in the group of  $\text{P/F } 0.21 < \text{P/F } 1.0$  (group 1,  $N = 8$ ). Seven cases were judged as suitable (black symbols), whereas one case was judged as not suitable (red symbol). Right: P/F ratio at 3  $\text{FiO}_2$  in the group of  $\text{P/F } 0.21 > \text{P/F } 1.0$  (group 2,  $N = 8$ ). All eight cases were judged as not suitable.

with many patients dying prior to an organ(s) becoming available for them. Unfortunately, approximately 80 percent of lungs offered for transplantation cannot be utilized due to poor lung function caused by factors including pulmonary edema and atelectasis.

Based on these numbers, the use of EVLP to recondition dysfunctional lungs could have a dramatic impact on the number of patients whose lives could be saved with lung transplantation. Indeed, EVLP has been clinically available in Canada for several years, and the Toronto Lung Transplant Program has increased its lung transplant volume by approximately 30 percent using this technology. In the U.S., the clinical use of EVLP is in its infancy but holds great promise for those programs that have the resources and clinical expertise to utilize it.

#### EVLP AT CLEVELAND CLINIC

We initiated EVLP research activity at Cleveland Clinic in 2011 in the McCurry lab. Several important questions regarding EVLP have been investigated using more than 50 rejected human lungs (Figure 1) and over 30 porcine lungs. One of the most critical questions is the accuracy of evaluating donor lung suitability for transplantation in EVLP, as this is key for patient safety. Parameters utilized to assess lung function for suitability for transplantation can include gas exchange ( $\text{PaO}_2/\text{FiO}_2$ ), lung compliance, vascular resistance, lung weight and visual findings.

Deciding whether perfused lungs are transplantable is frequently challenging, especially when  $\text{PaO}_2/\text{FiO}_2$  is in the marginal range of acceptability (around the current threshold of 300 mm Hg). In investigating this question, we identified the following important findings on the assessment of lung function in EVLP.

*Approximately 80 percent of lungs offered for transplantation cannot be utilized due to poor lung function caused by factors including pulmonary edema and atelectasis.*

- **The variability of  $\text{PaO}_2/\text{FiO}_2$  during cellular EVLP:** Previously,  $\text{PaO}_2/\text{FiO}_2$  was utilized in EVLP as a main indicator of oxygenation and considered constant at any  $\text{FiO}_2$ . However, we identified that variability of  $\text{PaO}_2/\text{FiO}_2$  exists at different  $\text{FiO}_2$  (0.21, 0.4 and 1.0) in EVLP.<sup>1</sup> Furthermore, we demonstrated that this variability is significant because the pattern of  $\text{PaO}_2/\text{FiO}_2$  at  $\text{FiO}_2$  of 0.21 <  $\text{PaO}_2/\text{FiO}_2$  at  $\text{FiO}_2$  of 1.0 was associated with substantially better oxygenation, higher pulmonary compliance and lower shunt fraction compared with the pattern of  $\text{PaO}_2/\text{FiO}_2$  at  $\text{FiO}_2$  of 0.21 >  $\text{PaO}_2/\text{FiO}_2$  at  $\text{FiO}_2$  of 1.0 in porcine lungs (Figure 2). This algorithm was consistent in human lungs and has significant implications for appropriately assessing and selecting suitable lungs for transplantation in EVLP.

- **A significant correlation between PaO<sub>2</sub>/FiO<sub>2</sub> and other physiological parameters (airway and vascular parameters):** In other novel work, we found that airway parameters (compliance) and vascular parameters (resistance) can be utilized as complementary parameters in the evaluation of lungs in EVLP.<sup>2</sup> Use of these supplementary data improves the accuracy and reliability of lung selection in EVLP.

Currently, Cleveland Clinic's Lung Transplant Program is participating in a clinical trial of EVLP — A Phase 2, Multicenter, Open-Label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the Sponsor Using the Toronto EVLP System — sponsored by United Therapeutics (Silver Spring, MD). In this study, donor lungs that are deemed not transplantable are procured and transported to a perfusion facility in Baltimore. During four to six hours of EVLP, lungs are reconditioned and assessed for transplantation suitability. When perfused lungs are judged as transplantable, they are transported to Cleveland Clinic, and lung transplantation is performed. Thus far, our patient survival utilizing this method is 100 percent.

This ability to utilize EVLP has brought other benefits as well. With EVLP as a backup, we can be more aggressive with lung procurement, resulting in conversion of some lungs that we thought needed EVLP into transplantable organs without using EVLP. Between February and September 2016, this has resulted in seven additional patients receiving transplants with 100 percent survival.

Overall, since initiating our clinical EVLP program, we have been able to provide transplantation to approximately 20 percent more patients in 2016 than at this time in 2015. We believe that the ability to offer the life-saving therapy of lung transplantation to more patients will continue to grow as we gain more experience and knowledge.



Dr. Okamoto, staff in the Transplantation Center, can be reached at [okamott@ccf.org](mailto:okamott@ccf.org) or 216.444.7917.



Dr. McCurry, Surgical Director of Lung Transplantation, can be reached at [mccurk@ccf.org](mailto:mccurk@ccf.org) or 216.445.9303.

**References**

1. Okamoto T, Wheeler D, Liu Q, Quintini C, Hata JS, McCurry KR. Variability in pressure of arterial oxygen to fractional inspired oxygen concentration ratio during cellular ex vivo lung perfusion: Implication for decision making. *Transplantation*. 2015;99(12):2504-2513.
2. Okamoto T, Wheeler D, Liu Q, Quintini C, Hata JS, McCurry KR. Correlation between PaO<sub>2</sub>/FiO<sub>2</sub> and airway and vascular parameters in the assessment of cellular ex vivo lung perfusion system. *J Heart Lung Transplant*. 2016 May 20. [Epub ahead of print].

## Predictors and Characteristics of Radiation Exposure in the MICU

Weighing risks and benefits of radiation-based imaging modalities

By Sudhir Krishnan, MD, and Jorge Guzman, MD

Critically ill patients admitted to a MICU are often subjected to multiple radiation-based diagnostic studies. The past decade has seen a dramatic rise in the utilization of radiation-based imaging studies, interventional procedures and computed tomography (CT). Medical radiation now accounts for a significant proportion of all radiation exposure in the United States. This has led to increased scrutiny of the stochastic effects (probability of cancer induction) of radiation and the subsequent risk of cancer induction.

In an effort to quantify and characterize medical radiation exposure in the MICU, we conducted a study to examine the radiation burden per episode of care in a cohort of patients admitted to the MICU at Cleveland Clinic's main campus. We found significant levels of exposure in some patients.

### STUDY DESIGN AND FINDINGS

To quantify radiation burden in the MICU, our study collated and summated radiation doses from all radiographic studies to arrive at a cumulative effective dose (CED) in millisieverts (mSv).<sup>1</sup>

The absorbed dose (energy deposited by ionizing radiation in biological tissues) is converted into an effective dose by correcting for both the type of radiation used (e.g., gamma versus x-rays)

and a weighting factor for the tissue or organ being irradiated. The effective dose calculation allows for summation of doses from all sources of radiation and represents the stochastic effect of low levels of ionizing radiation.

Eighty-four percent of the 4,155 admissions (3,333 unique patients) to the MICU in 2013 were exposed to at least one imaging study. Approximately 2.3 percent (N = 98) of MICU admissions were exposed to a CED greater than the annual federal occupational limit (50 mSv). Twelve admissions (nine MICU survivors) were exposed to doses greater than 100 mSv, similar to those accrued by some Japanese survivors of the atomic bomb blasts in 1945 (Figure 1). This dosage is statistically linked with cancer induction. Fifty-seven percent of the total radiation dose exposure came from CT scans (Figure 2).

### RISKS AND BENEFITS OF RADIATION-BASED IMAGING MODALITIES

The diagnostic utility of radiation imaging in the care of the critically ill should not be understated. However, patients in the MICU may be inadvertently exposed to very high dosages of radiation, due to the lack of a dose-tracking system. The risk of exposing patients to increasing radiation doses and the theoretical lifetime risk of cancer




Figure 1: Overall distribution of cumulative effective dose (CED) of radiation in the study population.

induction must be weighed against the purported benefits of further testing.

The proportion of patients exposed to radiation doses in excess of 50 mSV would increase dramatically if one were to collate the radiation burden acquired annually over the course of continued clinical care.

Focusing on statistical risks from radiation imaging should not distract attention from the potential benefits of imaging studies. Effective and judicious utilization of radiological resources provides great benefit to those needing diagnostic imaging studies. In the absence of a local, regional or national authority to monitor the cumulative doses accrued by patients, the requesting physician must be a responsible and economical consumer of radiological resources.

#### QUANTIFYING DOSES IN ONGOING CARE AND DOSE TRACKING

In our ongoing effort to quantify and explore radiation exposure in the critically ill, we are examining the annual radiation burden accrued by young patients (< 40 years of age) who survived an episode of critical illness in the MICU. Medical radiation doses accrued as a result of ongoing clinical care from various radiographic modalities both in inpatient and outpatient clinical settings, before and after MICU admission, will be summated to arrive at an annual CED. We hope to partner with other healthcare systems in our region to compare our practices and resulting radiation burden per episode of MICU care.

We ultimately hope to develop a software tool that tracks radiation doses and maintains a registry of radiation accrued per episode of clinical care, year and lifetime. Such a longitudinal registry would benefit clinical research and allow the requesting physician and patient to make an informed choice.




Dr. Krishnan, staff in Critical Care Medicine and Pulmonary Medicine, can be reached at [krishns2@ccf.org](mailto:krishns2@ccf.org) or 216.445.2570.



Dr. Guzman, staff in Critical Care Medicine and Chief Medical Officer at Cleveland Clinic Abu Dhabi, can be reached at [guzmanj@ccf.org](mailto:guzmanj@ccf.org).

Figure 2: Distribution of average CED per episode of care in the MICU by type of radiological study.



#### Reference

1. Krishnan S, Yella J, Narechania S, et al. The sicker you are, the more you glow — predictors and characteristics of cumulative radiation dose exposure estimates in the critically ill medical patient. *Chest*. 2015;148(4\_MeetingAbstracts):297A.

## Significant Progress in Understanding, Recognizing and Treating Alpha-1 Antitrypsin Deficiency

### Cleveland Clinic's Alpha-1 Antitrypsin Center plays key role in guideline update

James K. Stoller, MD, MS

Alpha-1 antitrypsin deficiency (AATD) is an autosomal codominant condition that predisposes to COPD and liver disease. Since its initial description in 1963, significant progress in understanding the pathogenesis, diagnostic strategies and treatment of AATD has been made. This progress is largely due to intensive research, both at the mechanistic and molecular levels, and to large, collaborative studies like the National Heart, Lung, and Blood Institute Registry of Individuals with Alpha-1 Antitrypsin Deficiency.<sup>1,2</sup> The Alpha-1 Foundation, a patient organization that supports research and serves as a broker between patients and the scientific, clinical and funding communities, has also worked to advance a cure for AATD. This brief review will highlight this progress, including Cleveland Clinic Respiratory Institute's long-standing contributions to understanding and managing individuals with AATD, culminating in participation in a recently updated clinical practice guideline for management of affected individuals.<sup>3</sup>

#### PROGRESS IN UNDERSTANDING AATD'S PATHOGENESIS

Major strides in understanding the pathogenesis of AATD include characterizing the *SERPINA1* gene (on the long arm of the 14th chromosome) and the AAT protein structure, and clarifying that the most common severely deficient allele, called Z, relates to a single amino acid substitution: lysine for glutamic acid at position 342. This substitution causes the Z-type protein to misfold, polymerize in the liver cell (hepatocyte) and bind less avidly to neutrophil elastase.<sup>4</sup> The result of this polymerization is that the Z-type protein is trapped within the hepatocyte, which lowers the serum and lung levels of AAT, thereby allowing unopposed proteolytic breakdown of elastin in the lung by neutrophil elastase within neutrophils, with consequent emphysema.

The pathogenesis of lung and liver diseases differ. Lung disease is related to a "toxic loss of function" characterized by inadequate amounts and impaired function of the abnormal AAT protein, which places the patient at risk for emphysema. In contrast, the associated liver disease (risk for liver scarring

[cirrhosis] and liver cancer [hepatoma]) relates to a "toxic gain of function," in which trapped, polymerized AAT protein in the hepatocytes (especially in ZZ homozygotes) creates a risk for hepatitis, cirrhosis and hepatoma.

#### ENHANCED AWARENESS AND DIAGNOSTIC STRATEGIES

Along with enhanced understanding of the pathogenesis of AATD has come increased appreciation of AATD's prevalence and, importantly, the profound degree to which AATD is globally under-recognized.<sup>5</sup> Current estimates suggest that 100,000 Americans have severe AATD but that fewer than 10,000 have been diagnosed. Affected individuals frequently experience long delays (i.e., five to eight years) between their first symptom (commonly dyspnea) and initial diagnosis of AATD; in one series, 43 percent of affected individuals reported seeing at least three physicians before the diagnosis was established.<sup>5,6</sup>

Awareness of persisting under-recognition of AATD has prompted the development of strategies to enhance diagnosis to make optimal management available sooner to individuals with AATD. At Cleveland Clinic, prompts in the electronic medical record encourage physicians to test for AATD whenever results of pulmonary function tests show fixed airflow obstruction. These prompts have been associated with a fourfold increase in appropriate testing frequency;<sup>7</sup> still, significant opportunities remain to ensure broader appropriate testing. Multicenter studies have shown that empowering respiratory therapists to counsel patients about testing, or to arrange testing at the point of care (i.e., during pulmonary function testing), helps detect affected individuals.<sup>8,9</sup>

#### CURRENT AND EMERGING THERAPIES

Finally, significant strides have been made in developing specific therapies for AATD in the 53 years since the condition was first described. Augmentation therapy — the intravenous infusion of purified, pooled human plasma AAT — is recommended for individuals with AATD and emphysema in the official guidelines of the American Thoracic Society and European Respiratory Society,<sup>10</sup> by the Canadian Thoracic Society,<sup>11</sup> and in

the Alpha-1 Foundation's most recent guidelines from a group of "alpha docs."<sup>3</sup> The weight of evidence, including three randomized, placebo-controlled trials, supports the efficacy of augmentation therapy in slowing the progression of emphysema.<sup>4</sup>

At the same time, novel therapies have been and are being actively investigated, including gene therapy with an adeno-associated virus vector given by whole limb perfusion or intrapleurally; administration of inhaled AAT or recombinant AAT; hyaluronic acid inhalation; RNA interference strategies to turn off production of Z protein; and administration of small molecule inhibitors of mutant AAT polymerization.

#### CLINICAL RESOURCE CENTERS KEY FOR PATIENTS

Patients with AATD undoubtedly benefit from the substantial and rapid scientific and clinical advancements in addressing AATD. To help direct patients toward clinicians who understand AATD, the Alpha-1 Foundation ([www.alpha1.org](http://www.alpha1.org)) has acknowledged Clinical Resource Centers (CRCs) with special expertise in managing patients with AATD. Cleveland Clinic's Alpha-1 Antitrypsin Center, one of the founding CRCs, draws from the expertise of colleagues in adult pulmonary medicine, dermatology, and adult and pediatric liver disease to treat these patients and to contribute to ongoing progress in understanding, diagnosing and treating the disease.



Dr. Stoller, Director of the Alpha-1 Antitrypsin Center and Chair of the Education Institute, can be reached at [stollej@ccf.org](mailto:stollej@ccf.org) or 216.444.1960.

#### References

- Schluchter MD, Barker AF, Crystal RG, Robbins RA, Stocks JM, Stoller JK, et al. The Alpha-1 Antitrypsin Deficiency Registry Study Group. A registry of patients with severe deficiency of alpha-1 antitrypsin: Design and methods. *Chest*. 1994;106(4):1223-1232.
- Crystal RG, Buist AS, Fallat RJ, Gadek JE, Schluchter MD, Stoller JK, et al. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and rate of FEV1 decline in subjects enrolled in the NHLBI Registry of Patients with Severe Deficiency of Alpha-1 Antitrypsin. *Am J Respir Crit Care Med*. 1998;158(1):49-59.
- Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, Hogarth DK, Knight SL, Stocks JM, Stoller JK, et al. The diagnosis and management of alpha 1-antitrypsin deficiency in the adult. *Chronic Obstr Pulm Dis (Miami)*. 2016; 3(3):668-682.
- Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, Stoller JK, McElvaney NG. Alpha 1-antitrypsin deficiency. *Nat Rev Dis Primers*. 2016;2:16051.
- Stoller JK, Brantly M. The challenge of detecting alpha 1-antitrypsin deficiency. *COPD*. 2013;10(Suppl 1):26-34.
- Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha 1-antitrypsin deficiency: a continuing problem. *Chest*. 2005;128(4):1989-1994.
- Jain A, McCarthy K, Xu M, Stoller JK. Impact of clinical support system in an electronic health record to enhance detection of alpha 1-antitrypsin deficiency. *Chest*. 2011;140(1):198-204.
- Rahaghi FF, Sandhaus RA, Brantly ML, Rouhani F, Campos MA, Strange C, Hogarth DK, Eden E, Stocks JM, Krowka MJ, Stoller JK. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. *COPD*. 2012;9(4):352-358.
- Stoller JK, Strange C, Schwarz L, Kallstrom TJ, Chatburn RL. Detection of alpha-1 antitrypsin deficiency by respiratory therapists: experience with an educational program. *Respir Care*. 2014;59(5):667-672.
- Stoller JK, Snider GL, Brantly ML, Fallat RJ, Stockley RA. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of patients with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003;168(7):818-900.
- Marciniuk DD, Hernandez P, Balter M, et al.; Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working Group. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. *Can Respir J*. 2012;19(2):109-116.

## The Integrated Respiratory Therapy Enterprise

RT integration drives efficiency, quality, cost savings across health system

By Madhu Sasidhar, MD

As healthcare systems consolidate to achieve efficiencies of scale, care integration is vital to improving the patient experience, ensuring quality and reducing costs. Recently, Cleveland Clinic health system integrated the respiratory care services provided by over 500 therapists at 13 locations in the Cleveland metropolitan area.

#### MOVING FROM A FRAGMENTED CARE EXPERIENCE

Respiratory therapy (RT) services within our health system in Northeast Ohio previously consisted of 12 business units at nine acute care facilities, one pediatric rehabilitation hospital and three freestanding emergency departments. Each unit created independent clinical protocols, policies and standards. Human resource management, education, research and quality improvement were integrated into the activities of individual units without coordination across units.

Owning only parts of our care continuum was inadequate, and the health system recognized the need for a deliberate strategy of integration for an optimized patient experience.

#### A FRAMEWORK FOR THE INTEGRATED RT ENTERPRISE

Integration efforts are critically dependent on support from senior leadership. During the early stages of planning, we sought participation from various stakeholders, including leaders of clinical institutes, regional hospital presidents, chief operating officers, operations, nursing and human resources. We identified barriers to success, including the need to have a local respiratory therapy leadership presence for daily operations. Many local leaders of respiratory care were in cross-functional roles that included oversight of services such as echocardiography and outpatient clinics. To provide a seamless transition, these expanded roles were preserved and supported following RT integration.

To support enterprise-level activities, existing roles were redefined and their scope of authority expanded. The RT director is a system-level role with responsibility for strategic planning and helping align goals of each unit with the organization's priorities. Two regional managers, with responsibility for four hospitals each, serve as cross-continuum leaders while providing operational support to local RT leaders. A lead RT supervisor or manager at each hospital is responsible for day-to-day operations and also serves as the main RT contact for other services at the hospital. Information technology, education, research and quality were each assigned coordinator positions with enterprisewide scope of activity.

#### IMPACTING QUALITY AND VALUE

Integrating RT services across our health system uniquely positions us to implement projects that impact quality and value. We have changed our RT productivity measurement system to better align with value-based care. Systemwide scheduling software will enable us to fully leverage a flexible staffing pool to meet staffing needs across multiple sites.

Enterprise quality improvement utilizes a monthly business review and scorecard to track and compare more than 70 clinical and operational metrics applicable to respiratory care. Our processes for regulatory compliance are being standardized along with enterprise-level RT policies and standard operating procedures.

Our integrated respiratory care service is continuously identifying opportunities for an expanded RT scope of practice that allows therapists to function at the highest level of their license. Specialized RT consult services, chronic disease management for COPD and emergency airway management are some of the areas we have identified and developed using our enterprise resources for education.

The integrated RT enterprise is one example of our health system's adaptation to provide a fully integrated care experience that continuously evolves and is optimized for value.



Dr. Sasidhar, Head of Respiratory Therapy and staff in the Respiratory Institute, can be reached at [sasidhm@ccf.org](mailto:sasidhm@ccf.org) or 216.445.0659.

#### Additional reading

- Stoller JK, Sasidhar M, Wheeler DM, et al. Team-building and change management in respiratory care: description of a process and outcomes. *Respir Care*. 2010;55(6):741-748.
- Smith M, Saunders R, Stuckhardt L, McGinnis JM. Committee on the Learning Health Care System in America, Institute of Medicine. *Best Care at Lower Cost: The Path to Continuously Learning Health Care in America*. Washington, D.C.: National Academies Press; 2013.

# Pulmonary Thromboendarterectomy for CTEPH

## Why it's underused despite high success rates

By Gustavo Heresi-Davila, MD

**C**hronic thromboembolic pulmonary hypertension (CTEPH) is a potentially deadly and underdiagnosed condition that develops from unresorbed pulmonary emboli. Our multidisciplinary team at Cleveland Clinic is one of just a handful across the U.S. that treat CTEPH using the complex surgical procedure known as pulmonary thromboendarterectomy (PTE).

### PTE: GRACE UNDER PRESSURE IS A MUST


Performing a PTE requires a dedicated team, a highly skilled surgeon and extreme efficiency under pressure. It involves quick yet painstaking removal of thin, scarred clot tissue lining the pulmonary arteries (Figure 1). The patient is rendered hypothermic to allow for periods of circulatory arrest on a cardiopulmonary bypass machine in order to enable a bloodless field.

Ideally, the procedure in each lung should be completed within 20 minutes to avoid the need for reperfusion. It's one of the most difficult surgeries we perform.


In 2010, we established a team to standardize protocols for PTE patient selection, preoperative evaluation, medical optimization and postoperative follow-up. Our team includes members from pulmonary medicine, cardiothoracic surgery, nuclear medicine, radiology, cardiology, anesthesiology and critical care medicine.

### SUCCESS RATES ABOVE 90 PERCENT

Cardiothoracic surgeon Nicholas Smedira, MD, first performed PTE at Cleveland Clinic in the 1990s. Over the past 20 years, Dr. Smedira and team have performed more than 180 PTE procedures, with current CTEPH success rates of 90 to 95 percent. Since 2010, operative mortality has dropped from around 12 percent to less than 4 percent, and volumes have increased. Between 2011 and September 2016, we performed 101 procedures (Figure 2). Rates of significant complications, such as confusion and disorientation from neurologic injury, or respiratory dysfunction due to lung injury, are now below 10 percent.



**Figure 1:** Pulmonary thromboendarterectomy for CTEPH involves quick but painstaking removal of thin, scarred clot tissue lining the pulmonary arteries. The residual scar is grasped and dissected from the lobar and segmental branches, as shown in the middle inset. The bottom inset shows an operative specimen. The procedure in each lung is ideally completed within 20 minutes to avoid the need for reperfusion.



**Figure 2:** Pulmonary thromboendarterectomy (PTE) experience, 1995 - September 2016 (N = 187)

These improvements over time are due mainly to major advances in the management of patients on perfusion therapy in anesthesiology and in postoperative critical care management. The surgical technique has remained much the same over the past 20 years.

### CTEPH: WHAT REFERRING CLINICIANS NEED TO KNOW

CTEPH should be included in every differential diagnosis of patients with pulmonary hypertension of unclear etiology, and even in those who merely have unexplained shortness of breath or exercise limitation.

Some patients don't exhibit pulmonary hypertension at rest but have symptoms during exercise, as on a cardiopulmonary exercise test or an exercise right heart catheterization. A lung ventilation/perfusion scan is the gold standard screening tool when CTEPH is suspected.

The estimated incidence of CTEPH within two years of initial pulmonary embolism is about 4 percent, but that number doesn't account for the many unrecognized pulmonary emboli. In fact, some 30 to 50 percent of patients diagnosed with CTEPH have no history of pulmonary emboli even though all are likely to have experienced one.

Of the 500,000 U.S. cases of pulmonary emboli per year, conservative estimates place the number of new CTEPH cases at about 2,400 to 5,000 annually. With only roughly 500 PTE operations being performed annually in the U.S., thousands of patients who might benefit from the procedure are not receiving it.

### DEBUNKING MISCONCEPTIONS AROUND PTE FOR CTEPH

Part of the reason is that even when CTEPH is diagnosed, misconceptions prevent physicians from referring patients for PTE.

Although about one-third of patients will have contraindications to surgery — most notably very distal and surgically inaccessible clots or significant comorbidities — many other factors are not contraindications, such as older age or obesity. In fact, we have performed successful PTEs in patients in their 70s and 80s and even in morbidly obese patients. Importantly, severe pulmonary hypertension of any degree is no longer a contraindication.

Another misconception is that CTEPH can be managed medically. Although anticoagulants are indicated to prevent further embolic events, they don't improve established CTEPH or pulmonary hypertension. One medication, riociguat (Adempas<sup>®</sup>), was recently approved by the FDA to treat CTEPH but is indicated only for patients who are not surgical candidates or who have residual or recurrent pulmonary hypertension after surgery.

We do not yet have hard and fast rules to determine which patients are nonoperable. The decision about operability is complex, largely subjective and shaped by the team's experience and expertise, which underscores the need for referral to an expert center.

The stakes are high. If the surgery is a possibility, it offers the best outcome for patients.



Dr. Heresi-Davila, Medical Director of the Pulmonary Thromboendarterectomy Program, can be reached at [heresig@ccf.org](mailto:heresig@ccf.org) or 216.636.5327.

## Novel Treatment for Obstructive Sleep Apnea: Hypoglossal Nerve Stimulation

On the frontier of OSA collaborative neurotherapeutics

By Reena Mehra, MD, MS; Alan Kominsky, MD; and Tina Waters, MD

Obstructive sleep apnea (OSA) is a condition characterized by repetitive upper airway collapse and that affects around 15 percent of the U.S. population. The intermittent episodes of upper airway compromise result in apneas (complete collapse) or hypopneas (partial upper airway collapse), with adverse physiologic consequences. These include episodic hypoxemia, hypercapnia, autonomic nervous system fluctuations and direct cardiac mechanical effects due to increases in negative intrathoracic pressure.

Researchers and clinicians are increasingly recognizing the importance of OSA treatment due to consistent findings from population-based studies that demonstrate the adverse health ramifications of untreated OSA.<sup>1</sup> These include longitudinal risk of increasing incident hypertension, insulin resistance/diabetes mellitus, coronary artery disease, heart failure, stroke and cardiovascular-specific mortality, along with data supporting increased vulnerability to sudden nocturnal cardiac death.

### OSA TREATMENT OPTIONS

Nasal continuous positive airway pressure (CPAP) therapy has long been considered standard first-line treatment of symptomatic OSA. Benefits include maintenance of airway patency, improved objective measures of sleep architecture and enhanced subjective quality of sleep.

More recently, oral appliances and upper airway surgical procedures such as uvulopalatoplasty have been introduced as alternative OSA treatment strategies; however, few additional novel therapies have been developed. In the clinical realm, treatment of OSA with CPAP has proved challenging from a patient compliance perspective, with general estimates ranging from 40 to 70 percent treatment adherence. Furthermore, suboptimal CPAP adherence in clinical trials poses a significant limitation in the accurate interpretation of results.



Figure 1: Inspire® Upper Airway Stimulation device. Image courtesy of Inspire Medical Systems Inc.




Figure 2: In this strip chart polysomnogram recording (approximately 2 min), the stimulator is turned ON (as verified by the bursting of the chin EMG) and then turned OFF, and then turned ON again. Abruptly, when the stimulator is turned OFF, there is upper airway obstruction, as illustrated by the flat nasal pressure signal, continued respiratory efforts, and a fall in oxygen saturation. (The thermistor signal is a thermal drift.) EEG=electroencephalogram. EOG=electrooculogram or eye movements. EMG=chin electromyogram. Snore=snore signal by microphone. Therm=thermistor at the nose for airflow. Nasal=nasal pressure transducer for flow. Chest and Abdm=chest and abdomen efforts, respectively, by inductance methods. SaO<sub>2</sub>=oxygen saturation by oximetry.

Figure and legend republished from Figure 2 (Kingman et al. *Respir Investig.* 2016 Jul;54(4):241-9. doi: 10.1016/j.resinv.2016.01.006. Epub 2016 Mar 18.) with permission from Elsevier.

Heterogeneity of OSA pathophysiology has also been established, involving interindividual variations in arousal threshold, loop gain, muscle responsiveness and critical closing pressure. For these reasons, development of novel OSA treatments targeting specific aspects of OSA pathophysiology is imperative to facilitate an individualized, precision medicine approach.

### HYPOGLOSSAL NERVE STIMULATION

Hypoglossal nerve stimulation is an innovative therapeutic approach available for the treatment of OSA for patients who are unresponsive to or intolerant of other treatments for OSA. This approach stems from the dysfunctional negative pressure genioglossus reflex in many OSA patients. In individuals without OSA, the genioglossus muscle (the primary pharyngeal dilator muscle) responds to negative intraluminal pressure with an increase in electromyographic activity. This is compromised in OSA due to neuromuscular dysfunction.

Initial experimental and small clinical trials showed improvement in airflow and enhanced upper airway stability without arousals during sleep or neuromuscular side effects. These data provided the basis to pursue larger clinical studies. Moreover, direct nasopharyngoscopic examination in these studies demonstrated not only enlargement and stabilization of the retrolingual space, but also the retropalatal airway, suggesting multilevel benefit.

The device operates by generating electrical stimulation, which advances the tongue forward and opens the pharyngeal airway during respiration. It consists of three implanted elements: a breathing sensor, a small electrical impulse generator and a hypoglossal nerve stimulator. Patients activate the system with a handheld remote control device.

Several devices are available, but only one has been approved by the FDA: the Inspire® Upper Airway Stimulation device (Inspire Medical Systems Inc.; Maple Grove, MN). The device is surgically implanted by placing a three-electrode wrap cuff on the distal medial branches of the hypoglossal nerve. The electrodes stimulate the anterior tongue protrusors, mainly consisting of the genioglossus muscle (Figure 1). An intercostal lead senses the fall in intrathoracic pressure during inspiration, thus providing a basis to synchronize muscle activation accordingly (Figure 2).<sup>2</sup>

### INTERVENTIONAL TRIAL DATA SUPPORTING BENEFITS OF HYPOGLOSSAL NERVE STIMULATION


In a multicenter, prospective, single-group cohort study, Inspire was implanted and activated one month later. Primary outcomes measured were the apnea hypopnea index (AHI) and oxygen desaturation index (ODI), standard indicators of sleep apnea severity.

Eligible participants had a body mass index < 32 kg/m<sup>2</sup> and moderate-to-severe OSA (AHI of 20 to 50 events per hour), and needed to show absence of complete concentric collapse of the velopharynx as observed on drug-induced sedation endoscopy.

The study documented a 68 percent reduction in the AHI at 12 months that was not otherwise explained by changes in weight, positional effects or sleep state differences. Secondary outcomes of subjective sleepiness and functional outcomes of sleep also demonstrated improvement at 12 months. A substudy at 12 months also showed that improvements in respiratory indices and measures of quality of life were reversed with transient cessation of therapy.

Currently, 36-month outcomes are available, which support durability of the beneficial effects. Interestingly, the amplitudes required for

## Individual Patient Outcomes



► **Figure 3:** Nine patients have undergone successful implantation of the device, with evidence of objective improvement of sleep apnea severity characterized by reduction of the apnea hypopnea index (AHI) from severe to near-normal range.

effective stimulation were similar at 12 months compared with 36 months, suggesting limited tachyphylaxis.

### CLEVELAND CLINIC CENTER OF EXCELLENCE

Cleveland Clinic's Sleep Disorders Center has been identified as a Center of Excellence for Inspire placement, leveraging cross-disciplinary sleep medicine collaborations involving neurology, otorhinolaryngology and pulmonary medicine. This multidisciplinary collaboration is critical to the program's success in melding the perspectives of neural innervation, respiratory physiology and surgical intervention.

Eligible candidates must meet four criteria:

- Age 18 years or older
- An AHI between 20 and 65
- A body mass index of less than 32 kg/m<sup>2</sup>
- Failure to respond to previous CPAP use

Prior to implantation, patients who fulfill these criteria undergo sedated endoscopy to ensure that their particular pattern of airway collapse is amenable to hypoglossal nerve stimulation therapy. Also, patients must have undergone a recent sleep study before implantation can be considered. Finally, a repeat sleep study must be performed one month postoperatively so that we can titrate the device to deliver its maximum therapeutic effect.

Thus far, nine patients have undergone successful implantation of the device, with evidence of objective improvement of sleep apnea severity characterized by reduction of the AHI from severe to near-normal range:  $42.9 \pm 11.5$  to  $6.0 \pm 2.7$  (Figure 3). Other outcomes such as patient-reported outcomes and cardiovascular measures are currently being collected to provide the platform for future investigation.



Dr. Mehra, Director of Sleep Disorders Research in the Sleep Disorders Center, can be reached at [mehrar@ccf.org](mailto:mehrar@ccf.org) or 216.444.8777.



Dr. Kominsky, staff in the Head and Neck Institute, can be reached at [kominsa@ccf.org](mailto:kominsa@ccf.org) or 216.839.3740.



Dr. Waters, staff in the Neurological Institute, can be reached at [waterst@ccf.org](mailto:waterst@ccf.org) or 216.444.8072.

### References

1. Mehra R. Obstructive sleep apnea research: challenges and new horizons. *Sleep Med.* 2014;15(5):483-484.
2. Strohl KP, Baskin J, Lance C, et al. Origins of and implementation concepts for upper airway stimulation therapy for obstructive sleep apnea. *Respir Investig.* 2016;54(4):241-249.

## Teaching Mechanical Ventilation in the 21st Century

### Bridging a gap between blackboards and bedsides

By Eduardo Mireles-Cabodevila, MD; Rendell Ashton, MD; Neal Chaisson, MD; Aanchal Kapoor, MD; Abhijit Duggal, MD, MPH, MS; Robert Chatburn, MHHS, RRT-NPS

The advent of positive pressure mechanical ventilation has arguably been one of the biggest advances in modern critical care medicine. Although its use was not routine until the 1960s and '70s, Galen described a similar concept as far back as the third century A.D.: "If you take a dead animal and blow air through its larynx [through a reed], you will fill its bronchi and watch its lungs attain the greatest distention."<sup>1</sup>

This simple manual process has now morphed into a series of highly complex machines and an endless variety of ventilatory options. Currently, there are over 300 different names for modes of ventilation in the United States alone. Lack of a systematic taxonomy to describe modes presents significant problems. Nomenclature is at the whim of ventilator manufacturers, and trendy mode names can be confusing or misleading. As a result, physicians often restrict teaching and practice to the most basic modes of ventilation. Those who venture beyond this often do so with an incomplete understanding of how the ventilator and patient truly interact.

Following the work of Robert Chatburn, MHHS, RRT-NPS, Respiratory Therapy Research Manager at the Respiratory Institute, on a taxonomy of mechanical ventilation, our group of 10 educators began to discuss the growing chasm between current teaching paradigms and ventilator utilization at the bedside. We concluded that medical education in this area felt as antiquated as Galen's reed.

### A NOVEL COURSE ON THE PRINCIPLES AND APPLICATION OF MECHANICAL VENTILATION

Our team worked to address several educational gaps by creating a three-phase curriculum on the principles and application of mechanical ventilation. The first phase focuses on establishing a standardized ventilator taxonomy<sup>2</sup> and learning to choose a mode of mechanical ventilation based on physiologic objectives and clinical goals. Trainees also learn to optimize patient interactions according to specific algorithms (Figure). Trainees complete an interactive, online curriculum of 16 modules before moving to the next phase. These narrated modules include embedded graphics, quizzes and links to supporting literature and online ventilator simulators.

The second and third phases of our curriculum occur during an eight-hour Mechanical Ventilation Skills course at Cleveland Clinic's Simulation and Advanced Skills Center. The Simulation Center and its multidisciplinary staff allow users the flexibility to create a realistic ICU atmosphere and to utilize high-fidelity ventilator waveform simulators, interactive monitors and realistic patient profiles.

Phase two begins with a didactic lecture reviewing key concepts from the self-guided online modules, followed by a hands-on rotation through six skills stations where a facilitator assists learner interaction with ventilators. This phase reinforces concepts of mode taxonomy and patient ventilator interaction and allows safe learning of ventilator manipulation. It also teaches trainees to evaluate the response of each mode to different physiological conditions and reinforces the use of appropriate modes to achieve specific ventilation goals.

Phase three occurs during the afternoon portion of the simulation course. Learners move into small groups, where they are exposed to three ICU-based scenarios (ARDS, status asthmaticus and reversal of paralytic medications). In each scenario, teams receive basic clinical information and are exposed to a simulated patient interacting with a ventilator. Learners must choose an appropriate ventilator mode and optimize the settings. Instructors vary patient physiology and patient/ventilator interactions based on a predetermined algorithm created by our team.

Each scenario has specific objectives to reinforce concepts from phases one and two and is designed to be realistic and fully interactive. Time for targeted debriefing and review of the learning objectives is a key element of each scenario.

Finally, groups rotate through an asynchrony troubleshooting workshop. The workshop is designed to introduce a method to evaluate patient-ventilator interactions systematically and to recognize forms of asynchrony correctly. Trainees learn via hands-on interaction with ventilators and a high-fidelity lung simulator with preprogrammed asynchronous activity.

### BUILDING BRIDGES TO IMPROVED PATIENT CARE

Our Mechanical Ventilation Skills course represents the Respiratory Institute's commitment to educational excellence and innovation. Using leading-edge institutional resources, international expertise in mechanical ventilation and the latest concepts in education theory, we are building bridges between the classroom and the bedside. Our innovative approach to simulation and teaching is helping trainees identify the best ways to optimize both patient comfort and lung-protective ventilation with modern mechanical ventilators.

**RESPIRATORY INSTITUTE BASIC MECHANICAL VENTILATION COURSE** **Cleveland Clinic**

**Breath control variable** + **Breath Sequence** + **Targeting scheme** = **Mode**

Volume or Pressure Control + CMV IMV CSV + Intelligent Dual Adaptive Biovariable Optimal Servo Set point = VC-CMV's PC-IMV's,5

**Step 1: Breath control variable**

$P = E \times V + R \times \dot{V}$

**Step 2: Breath Sequence**

	Trigger	Cycle	Breath Sequence	Type of breath
Mandatory	Ventilator controls one or both		CMV	All mandatory
Spontaneous	Patient controls both		IMV CSV	Mandatory and spontaneous All spontaneous

**Step 3: Targeting Scheme**

Set-point (s) - all targets set by operator  
 Dual (d) - ventilator switches PC and VC within a breath  
 Bio-variable (b) - inspiratory pressure varies randomly  
 Servo (r) - inspiratory pressure proportional to patient inspiratory effort  
 Adaptive (a) - ventilator adjusts pressure to meet VT target  
 Optimal (o) - adaptive targeting to minimize a function (WOB)  
 Intelligent (i) - tools of artificial intelligence

**Step 4: Choose Mode**

CLINICAL OBJECTIVE	Mandatory Breaths Only			Spontaneous Breaths Only		
	PC-CMV's	VC-CMV's	PC-CMV's <sup>1</sup>	PC-CSV's	PC-CSV's <sup>1</sup>	PC-CSW
Minute Ventilation	set vs NOT vs	set vs AND vs	set vs AND vs	set vs, NOT vs	set vs, NOT vs	set vs NOT vs
Prevent VILI	passive breaths only	active and passive	passive - some active	no protection	some protection	no protection
Synchrony	flow sync	flow & cycle sync	flow sync	flow/cycle sync	flow & cycle sync	flow/cycle sync
WOB	WOB=vent constant	WOB=vent with effort	WOB=vent with effort	WOB=vent constant	WOB=vent with effort	WOB=vent with effort
Liberation	no helpful features	no helpful features	possible auto-vent	no helpful features	possible auto-vent	no helpful features

contraindicated if increased respiratory drive (eg, metabolic acidosis) Green = OK, Yellow = caution, Red = not recommended

Figure: Fellows learn ventilator taxonomy in a systematic fashion. This allows caregivers to optimize ventilator settings by more fully understanding the individual merits and limits of each mode.

## Case Study: Managing Primary Immunodeficiencies

### Complex cases requiring multidisciplinary care

By James Fernandez, MD, PhD, and Maria Barcena Blanch, MD

#### PRESENTATION

A 57-year-old man with history of COPD, coronary artery disease (CAD), and atrial fibrillation required admission to the hospital due to worsening cardiac symptoms associated with CAD and aortic insufficiency.

Throughout his teenage years and early 30s, he had necrotic skin ulcerations involving his upper and lower extremities that required two- to four-week courses of parenteral antibiotic therapy four to five times per year. His symptoms subsided by the age of 40, with spontaneous resolution of his recurrent skin lesions. He had no further history of recurrent infections involving skin or other systems after the age of 40. However, he developed a severe postoperative infection after a coronary artery bypass graft (CABG) and aortic valve repair performed at age 53, resulting in mediastinitis requiring surgical intervention, skin flap and prolonged IV antibiotic course.

During the current admission, aortic valve replacement and redo CABG were recommended by the cardiac surgical team. Due to this history of postoperative infection and poor wound healing, he was deemed a high-risk surgical candidate and required preoperative evaluation by immunology and infectious disease.

#### EVALUATION

The physical exam was fairly unremarkable. His labs revealed a WBC of  $8.36 \times 10^3/\mu\text{L}$ , hemoglobin of 10.7 g/dL, hematocrit 33.6 percent, MCV 88 fL, platelets  $462 \times 10^3/\mu\text{L}$ , total protein 6.8 g/dL, with normal liver and renal function tests. Immunologic and infectious workup showed IgE 16.7 mg/dL, IgA 483 mg/dL, IgG 1020 mg/dL, IgM 69 mg/dL, protective titers against tetanus and pneumococcal serotypes, normal LTT mitogen, syphilis IgG negative, nonreactive HIV, and negative hepatitis screen and fungal battery. He underwent redo open heart surgery consisting of aortic valve replacement and CABG without intraoperative complications.

#### POSTOPERATIVE COMPLICATIONS


His postoperative course was complicated by leukocytosis (WBC  $27.6 \times 10^3/\mu\text{L}$ ; neutrophils 87 percent, lymphocytes 6.8 percent, monocytes 1.4 percent) and increased ESR (39), wound dehiscence, sternal wound osteomyelitis and development of enterococcal bacteremia. He required treatment with wound vac placement and prolonged IV vancomycin.

Peripheral blood smear showed leukocytosis with neutrophilia with mature segmented neutrophils. Interestingly, the majority of neutrophils showed hyposegmentation, particularly bilobed nucleus similar to Pelger-Huet anomaly, and occasionally small, fragmented nuclei (microlobes) were present. All neutrophils demonstrated pale cytoplasm because of significant decrease in cytoplasmic granulation (Figure 1A). Myeloperoxidase stain showed mild myeloperoxidase reaction in neutrophils; however, it was significantly reduced compared with the reactions in normal neutrophils from a healthy donor (Figure 1B). Although only a few eosinophils were present in the peripheral blood smears, cytoplasmic granules appeared decreased. No other inclusions in the granulocytes or immature granulocytes were noted.

#### A CLOSER LOOK AND AN ANSWER

Figure 2A-C shows the ultrastructure of granulocytes by electron microscopy, demonstrating mature, segmented neutrophils with many bilobed forms and occasional microlobes. Segmented neutrophils had abundant cytoplasm, rich glycogen particles and Golgi zone. Primary (azurophilic) and tertiary granules were present, but decreased in the neutrophils. Secondary (specific) granules were markedly decreased or absent in the neutrophils examined.

Figure 1 A: Peripheral blood smear showing hyposegmented neutrophils, particularly bilobed neutrophils with significantly reduced cytoplasmic granulation; representative cell is highlighted in box (Wright-Giemsa stain x1000). B: Myeloperoxidase stain shows reduced myeloperoxidase reaction in patient's neutrophils. Normal reaction pattern from healthy donor is shown in insert (images x1000).



Eduardo Mireles-Cabodevila, MD, Program Director, Critical Care Medicine Fellowship, can be reached at [mirelee@ccf.org](mailto:mirelee@ccf.org) or 216.445.2523.



Rendell Ashton, MD, Program Director, Pulmonary and Critical Care Medicine Fellowship, can be reached at [ashtonr@ccf.org](mailto:ashtonr@ccf.org) or 216.636.5321.



Neal Chaisson, MD, Associate Program Director, Pulmonary and Critical Care Medicine Fellowship, can be reached at [chaisn@ccf.org](mailto:chaisn@ccf.org) or 216.444.7943.



Aanchal Kapoor, MD, Associate Program Director, Critical Care Medicine Fellowship, can be reached at [kapoor@ccf.org](mailto:kapoor@ccf.org) or 216.444.4100.




Abhijit Duggal, MD, MPH, MS, Associate Program Director, Critical Care Medicine Fellowship, can be reached at [duggala2@ccf.org](mailto:duggala2@ccf.org) or 216.444.4838.



Robert Chatburn, MHS, RRT-NPS, Research Program Manager, Respiratory Therapy Program, can be reached at [chatbur@ccf.org](mailto:chatbur@ccf.org) or 216.445.1424.

#### References

- Colice GL. Historical perspective on the development of mechanical ventilation. In: Tobin M, ed. *Principles & Practice of Mechanical Ventilation*. 2nd ed. New York, NY: McGraw-Hill; 2006.
- Chatburn RL, El-Khatib M, Mireles-Cabodevila E. A taxonomy for mechanical ventilation: 10 fundamental maxims. *Respir Care*. 2014;59(11):1747-1763.



► **Figure 2:** A: Ultrastructure of neutrophils showed predominantly bilobed neutrophils with occasional microlobes (x4,800). B-C: Higher magnification of the neutrophils showed decreased primary (azurophilic; red arrow) and tertiary (blue) granules. Specific (secondary) granules were not present (x23,000).

A heterozygous variant of unknown significance, c.653T>C (p.Val218Ala), was identified in exon 2 of the *CEBPE* gene. A second mutation of the *CEBPE* gene was not detected via gene sequencing, but deletion/duplication analysis was not completed. The presence of large deletions or duplications could not be ruled out. Other deep intronic pathogenic variants as well as variants in other regulatory regions also could not be ruled out.

Based on these findings, we diagnosed the patient with specific granule deficiency. This patient experienced significant burden of disease from infancy to adulthood. Even after remission of his skin lesions, he remains at elevated risk for severe infections, as demonstrated by mediastinitis, osteomyelitis and bacteremia after surgical or invasive interventions.

**ADULT IMMUNODEFICIENCY CLINIC: A COLLABORATIVE APPROACH**

This case demonstrates the complex characteristics of primary immunodeficiencies (PID). Patients with PID are at risk of multiple complications, including autoimmune disease, which develops in 20 to 25 percent of patients.<sup>1</sup> These patients require continued monitoring not only for infections but also for granulomatous disease of the lungs, autoimmune disorders, lymphoma, malabsorption and other complications. For these reasons, a team approach is vital to the overall care of our PID patients.

The Adult Immunodeficiency Clinic within Cleveland Clinic's R.J. Fasenmyer Center for Clinical Immunology works closely with pulmonologists, rheumatologists, hematologists, oncologists and gastroenterologists to provide the best care for these patients. We

and our colleagues frequently make decisions about care as a team, and constant communication among physicians is a necessity.

In the end, patients are better served and appreciate a collaborative effort by multiple physicians with specific expertise in managing their primary immunodeficiency and the complications related to it. With a growing number of adult immunodeficiencies being identified,<sup>2,3</sup> our Adult Immunodeficiency Clinic is fully committed to advancing the care of patients and initiating new research projects in this growing and exciting field.

**References**

1. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. *J Clin Immunol.* 2008;28(suppl 1):S42-S45.
2. Notarangelo, Fischer A, Geha RS, et al., for International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies. Primary immunodeficiencies: 2009 update. *J Allergy Clin Immunol.* 2009;124(6):1161-1178.
3. Yao Q, Shen M, Fernandez J. NOD2-associated autoinflammatory disease and immune deficiency. *J Allergy Clin Immunol Pract.* 2016;4(4):780-782.



Dr. Fernandez, staff in the Department of Allergy and Clinical Immunology, can be reached at [fernanj2@ccf.org](mailto:fernanj2@ccf.org) or 216.444.6933.

Dr. Barcena Blanch is a 2016 graduate of our Allergy and Clinical Immunology fellowship.

**Drs. Erzurum, Kotloff Receive ATS Awards**



**Serpil Erzurum, MD**, Chair of Lerner Research Institute and staff in the Department of Pulmonary Medicine, received the Recognition Award for Scientific

Accomplishments at the 2016 American Thoracic Society annual meeting for her work "Cellular and Molecular Mechanisms in Pulmonary Hypertension." She also delivered a keynote address, "Biomarkers for Precision Medicine in Asthma."

**Robert Kotloff, MD**, Chair of the Department of Pulmonary Medicine, received the Outstanding Educator Award at the 2016 American Thoracic Society annual meeting as recognition for lifetime contributions in education and mentoring in the field of pulmonary medicine.

**Dr. Budev Receives Endowed Chair**



A \$2 million gift by Macon and Joan Brock has established The Macon and Joan Brock Endowed Chair, which will support lung transplant research and education. **Marie Budev, DO, MPH**, is the inaugural chair holder.



Dr. Budev is Medical Director of Cleveland Clinic's Lung and Heart-Lung Transplant Program, one of the largest programs of its kind in the country. In addition to her transplant responsibilities, she is actively involved in the internal medicine residency program as Associate Program Director.

Dr. Budev treats all types of end-stage lung disease, including congenital heart-lung diseases, interstitial lung disease, COPD and pulmonary hypertension. Her research has focused on antibody-mediated rejection and selection of lung transplant candidates.

**Textbooks**

**Daniel Culver, DO; Robert Kotloff, MD; Atul Mehta, MD; and James K. Stoller, MD, MS**, served as editors of textbooks published in 2015-2016 and pictured here.

**News Briefs**



**Dr. Erzurum Named Chair of Lerner Research Institute**

**Serpil Erzurum, MD**, was named Chair of Cleveland Clinic's Lerner Research Institute in August 2016. She is the founding Chair of the Department of Pathobiology. Dr. Erzurum's contributions and leadership in pulmonary research have led to diagnostic and therapeutic advances in asthma and pulmonary hypertension and helped identify human physiologic adaptive responses to high-altitude hypoxia. She has published more than 200 peer-reviewed articles and has been principal investigator on more than 20 federal grants with more than \$60 million in research

funding, including several large, multi-investigator program project grants and network trials. She is a practicing pulmonologist and Cleveland Clinic's lead for the Clinical and Translational Science Center of Cleveland.

In addition to her leadership at Cleveland Clinic, Dr. Erzurum has served the profession as Chair of the Allergy, Immunology and Inflammation Assembly of the American Thoracic Society; Councilor of the Association of American Physicians; member of the NHLBI Advisory Council; and Chair of the Pulmonary Disease Board of the American Board of Internal Medicine.

# NewsBriefs

## COPD Center Provides Comprehensive, Multidisciplinary Care

The Center for Comprehensive Care in COPD (COPD Center) was established with the aim of providing comprehensive and multidisciplinary care to COPD patients evaluated and managed at Cleveland Clinic Respiratory Institute. The team consists of pulmonologists, thoracic radiologists, thoracic surgeons, physician assistants, nurses and respiratory therapists who specialize in the treatment of COPD. The COPD Center's regular meetings provide an excellent, multidisciplinary venue for discussing management of challenging patients, appropriateness of lung volume reduction modalities and the latest innovations in the management of COPD patients.

The COPD Center maintains a referral clinic as well as a COPD exacerbation clinic that provides early follow-up to those patients recently discharged from the hospital. COPD Center physicians have extensive experience in the assessment of patients for

advanced surgical procedures such as lung volume reduction surgery and lung transplantation. The center actively participates in clinical trials of various modalities of bronchoscopic lung volume reduction and has long-standing experience in the evaluation and treatment of patients with alpha-1 antitrypsin deficiency. By including representatives from Cleveland Clinic's regional hospitals, the COPD Center also leads institutional and enterprisewide initiatives for improving the care of patients with COPD, such as the COPD care path and electronic inhaler monitoring program.

To refer a patient, please call **216.444.6503** and ask to be directed to **The COPD Center.**

### Medical Director

Umur Hatipoğlu, MD

### Pulmonologists

Loutfi A. Aboussouan, MD  
Joseph Cicens, MD  
Thomas Gildea, MD, MS  
Michael Machuzak, MD  
Atul Mehta, MD  
Kathrin Nicolacakis, MD  
Bohdan Pichurko, MD  
James K. Stoller, MD, MS

### Thoracic Surgery

Sudish Murthy, MD, PhD

### Thoracic Radiology

Rahul Renapurkar, MD

### Respiratory Therapy

Richard Rice, RRT

### Research Coordinator

Yvonne Meli, RN

## Respiratory Institute Selected Clinical Trials

Consider offering your patient enrollment in a leading-edge clinical research trial at our Respiratory Institute. Obtain further information by contacting the study coordinator or principal investigator.

### ASTHMA

#### Functional Medicine in Asthma (FAst) Study

The objective of this study, sponsored by executive administration, is to determine if standardized guideline-based specialist asthma treatment with respect to asthma control (as measured by ACQ/AQLQ) is equivalent to guideline-based specialist treatment plus additional Functional Medicine management approach.

**ELIGIBILITY:** Women and men ages > 18 and < 65; nonsmokers or former smokers, with 15 pack-years or less history of smoking; clinical history consistent with moderate to severe asthma; measures of airflow obstruction and reactivity consistent with asthma (12% BD response and/or positive methacholine challenge test) historically or at initial/screening visit; FEV1 between 40 and 100% predicted post bronchodilator; uncontrolled asthma categorized (ACT ≤ 19); willing to be seen in Asthma Center and willing to consider Functional Medicine approach as an add-on to Asthma Center care. Exclusion criteria include life-threatening asthma; any disorder, including but not limited to gastrointestinal, renal, neurological, infectious, endocrine, metabolic or other physical impairment, that is not stable in the opinion of the investigator; clinically important pulmonary disease other than asthma; controlled asthma defined by stability and by ACT > 19; current asthma exacerbations; stable lung function.

**PRINCIPAL INVESTIGATOR:**  
Sumita Khatri, MD, MS

### STUDY COORDINATOR:

JoAnne Baran-Smiley, BSN, RN  
216.444.5023

### LYMPHANGIOLEIOMYOMATOSIS

#### Registry: Multicenter International Durability and Safety of Sirolimus in Lymphangioleiomyomatosis Trial (MIDAS Trial)

Sponsored by NIH via Cincinnati Children's Hospital Medical Center, this study is a real-world, long-term, prospective, observational drug registry of LAM patients taking or considering taking mTOR inhibitor therapy (sirolimus or everolimus) based on clinical indications. Patients will be diagnosed, treated and followed by their physician according to routine clinical practice.

**ELIGIBILITY:** The study will enroll LAM patients taking or considering taking mTOR inhibitors from participating clinics in academic health centers and community hospitals. All LAM patients who are chronically treated, newly treated or who may be considered for treatment with mTOR inhibitors are eligible to enroll in the study. Patients who have failed or have been intolerant to mTOR inhibitors will also be recruited. Inclusion criteria include: female LAM patients, age 18 or over; signed, dated informed consent form; diagnosis of TSC or LAM; currently on mTOR inhibitors, and previously intolerant of or have failed mTOR inhibitors, or may be considered for mTOR therapy. Exclusion criteria include: inability to attend clinic visit for LAM evaluation at least once per year; inability to give informed consent; and inability or unwillingness to perform pulmonary function testing.

### PRINCIPAL INVESTIGATOR

Robert Kotloff, MD

### STUDY COORDINATOR

JoAnne Baran-Smiley, BSN, RN  
216.444.5023

### LUNG TRANSPLANT

#### A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection

Sponsored by Gilead Sciences Inc., this is a randomized, double-blind, placebo-controlled study evaluating the effect of presatovir on efficacy, PK, safety and tolerability in lung transplant recipients with RSV infection.

**ELIGIBILITY:** Key inclusion criteria include: males and females ≥ 18 years of age who have received an LT (single or double) or heart/lung transplant > 90 days prior to screening; confirmed to be RSV-positive by local PCR ≤ 7 days prior to IMP administration; new onset or acute worsening, if the symptom is chronic, of at least one of the following respiratory symptoms ≤ 7 days prior to IMP administration on Day 1/baseline: nasal congestion, earache, runny nose, cough, sore throat, shortness of breath or wheezing. Key exclusion criteria include: use of any investigational agents within specified time frame; use of a strong or moderate cytochrome P450 enzyme (CYP); recipient of any other organ transplant prior to screening, with the exception of an LT (single or double) or heart/lung transplant; known viral coinfection in the upper or lower respiratory tract ≤ 14 days prior to screening; active systemic infection or infectious pneumonia

of any etiology; clinically significant kidney dysfunction; clinically significant liver function test abnormalities; and clinically significant elevations in total bilirubin.

**PRINCIPAL INVESTIGATOR:**

Marie Budev, DO, MPH

**STUDY COORDINATOR:**

JoAnne Baran-Smiley, BSN, RN  
216.444.5023

### SLEEP MEDICINE

**Sleep Apnea and Atrial Fibrillation Electrophysiology: Biomarkers and Evaluating Atrial Triggers (SAFEBEAT)**

The SAFEBEAT study is an NIH-supported study designed to examine the mechanisms underlying sleep-disordered breathing and paroxysmal atrial fibrillation.

**ELIGIBILITY:** Individuals 18-80 years old who have been diagnosed with paroxysmal atrial fibrillation and hypertension and have a BMI of 35 or greater. Participants must be able to participate in up to two overnight sleep studies and must not be on any current treatment for sleep apnea.

**PRINCIPAL INVESTIGATOR:**

Reena Mehra, MD, MS

**STUDY COORDINATORS:**

Joan Aylor | 216.445.1698

Rawan Nawabit | 216.445.1593

### PULMONARY HYPERTENSION

**A Phase 3, Placebo-Controlled, Double-Blind, Randomized, Clinical Study to Determine Efficacy, Safety and Tolerability of Pulsed, Inhaled Nitric Oxide (iNo) Versus Placebo in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH)**

Sponsored by Bellerophon Pulse Technologies, this study's main objective is to evaluate the efficacy of inhaled nitric oxide (INO) using the INOpulse device as compared to placebo in patients with PAH.

**ELIGIBILITY:** Men or women 18-80 years of age diagnosed with WHO Group 1 PAH who are on a stable dose of at least one PAH specific therapy, who are using oxygen therapy, mPAP > 25 mm Hg, PCWP < 15, PVR > 5 Wood units. Exclusion criteria include moderate to severe restrictive lung disease, undergoing dialysis, the use of a CPAP or BiPAP device and riociguat as therapy.

**PRINCIPAL INVESTIGATOR:**

Gustavo Heresi-Davila, MD

**STUDY COORDINATOR:**

Holly Radice | 216.444.2140

**A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of UBenimex in Patients with Pulmonary ARterial HYpertension (WHO Group 1) (LIBERTY)**

Sponsored by Eiger BioPharmaceuticals, this study's main objective is to evaluate the safety and efficacy of ubenimex as compared with placebo in patients with Pulmonary Arterial Hypertension.

**ELIGIBILITY:** Men or women 18-75 years of age diagnosed with WHO Group 1 PAH, on a stable dose of PAH specific therapy for at least three months prior to screening, mPAP > 25 mm Hg, PCWP < 15, PVR > 3.75 Wood units. Exclusion criteria include significant restrictive lung disease, history of portal hypertension or liver disease, and having an active infection.

**PRINCIPAL INVESTIGATOR:**

Kristin Highland, MD, MS

**STUDY COORDINATOR:**

Holly Radice | 216.444.2140

### INTERVENTIONAL BRONCHOSCOPY

**Safety and Effectiveness of the Spiration Valve System in Air Leaks: VAST (Valves Against Standard Therapy)**

This study is designed to evaluate the clinical effectiveness of the SVS for treatment of prolonged air leak in non-mechanically ventilated patients.

**ELIGIBILITY:** Adults with an air leak  $\geq$  100 mL/min, as measured by a digital thoracic drainage system; air leak present on at least the fifth day following origination. Exclusion criteria include air leak only on forced exhalation or cough; primary pneumothorax; prior interventions including pleurodesis, surgery, blood patch and pneumoperitoneum or valve placement.

**PRINCIPAL INVESTIGATOR:**

Michael Machuzak, MD

**STUDY COORDINATOR:**

Yvonne Meli, RN | 216.445.4215

### SARCOIDOSIS

**A Multiple-Dose, Subject- and Investigator-Blinded, Placebo-Controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients with Pulmonary Sarcoidosis**

Sponsored by Novartis, this is a Phase 2 trial investigating the effect of ACZ885, a monoclonal antibody targeting interleukin-1 beta, versus placebo on the clinical disease activity of sarcoidosis patients as measured by the change from baseline in percent predicted forced vital capacity (FVC) at week 24.

**ELIGIBILITY:** Ages 18-80 with biopsy-proven, clinically active disease having all of the following criteria: MMRC dyspnea scale > 1, 2; threshold FVC 50-80% of predicted; evidence of parenchymal lung involvement by HRCT. Subjects must weigh at least 50 kg. Subjects must be able to communicate well with the investigator and to understand and comply with the requirements of the study. Disease duration of > 1 year. Selected exclusion criteria include current inhaled use of tobacco products; known hypersensitivity to canakinumab; prior treatment with any biologic drug targeting the immune system within 180 days of randomization or history of any previous use of rituximab; FVC < 50% of predicted; diagnosis of pulmonary hypertension requiring treatment.

**PRINCIPAL INVESTIGATOR:**

Daniel Culver, DO

**STUDY COORDINATOR:**

Christopher Estling | 216.445.8951

### INTERSTITIAL LUNG DISEASE

**Genetic Risk for Granulomatous Interstitial Lung Disease**

The objective of this NIH-supported study is to identify genetic risk factors for sarcoidosis.

**ELIGIBILITY:** Patient must be Caucasian. Biopsy-proven sarcoidosis or Lofgren's syndrome and at least one of the following, documenting pulmonary disease involvement due to sarcoidosis: a biopsy from the lung (either via bronchoscopy or otherwise) or chest lymph nodes demonstrating granulomas; pulmonary parenchymal involvement with Scadding chest x-ray stage I, II, III, IV, in the past or present; abnormal spirometry and/or DLCO (< 80% predicted). Exclusion criteria include positive lung washing or biopsy cultures for fungi or mycobacterial disease or the inability to undergo venipuncture.

**PRINCIPAL INVESTIGATOR:**

Daniel Culver, DO

**STUDY COORDINATOR:**

Christopher Estling | 216.445.8951



# Respiratory Institute Staff Directory



**Herbert P. Wiedemann, MD, MBA**  
 Chairman, Respiratory Institute  
 216.444.8335  
 Specialty Interests: critical care, general pulmonary medicine

**Departments of Pulmonary & Critical Care Medicine**



**Robert Kotloff, MD**  
 Chairman, Department of Pulmonary Medicine  
 216.445.9460  
 Specialty Interests: general pulmonary medicine, lung transplantation, LAM



**Loutfi Aboussouan, MD**  
 Joint Appointment with Sleep Center  
 216.444.0420  
 Specialty Interests: general pulmonary medicine, neuromuscular diseases, sleep medicine, long-term ventilator care



**Muzaffar Ahmad, MD**  
 216.444.6506  
 Specialty Interests: general pulmonary medicine



**Olufemi Akindipe, MD**  
 216.444.0569  
 Specialty Interest: lung transplantation



**Mohammed Al-Jaghbeer, MD**  
 216.476.7983  
 Specialty Interests: critical care, general pulmonary medicine



**Narendrakumar Alappan, MD**  
 Director, Respiratory Therapy Care Services at Fairview Hospital  
 216.476.7983  
 Specialty Interests: critical care, general pulmonary medicine



**Francisco Almeida, MD, MS**  
 Director, Interventional Pulmonary Medicine Fellowship Program  
 216.444.1908  
 Specialty Interests: advanced diagnostic and interventional bronchoscopy, lung cancer, pleural disease



**Rendell Ashton, MD**  
 Education Officer; Director, Pulmonary and Critical Care Fellowship Program  
 216.636.5321  
 Specialty Interests: critical care, medical education



**David Berzon, MD**  
 440.312.7140  
 Specialty Interests: general pulmonary medicine, critical care, sleep medicine



**Akhil P. Bindra, MD**  
 Director, Hillcrest Hospital ICU  
 440.312.7140  
 Specialty Interests: critical care, general pulmonary medicine, sarcoidosis, interstitial lung disease



**Eileen Bishop, DO**  
 216.444.7523  
 Specialty Interest: critical care



**James Blackburn, DO**  
 216.445.7772  
 Specialty Interest: general pulmonary medicine



**Marie Budev, DO, MPH**  
 Medical Director, Lung and Heart-Lung Transplantation  
 216.444.3194  
 Specialty Interests: lung transplantation, gender-specific pulmonary issues



**Ronald Burwinkel, MD**  
 440.312.7140  
 Specialty Interests: critical care, general pulmonary medicine



**Robert Castele, MD**  
 440.878.2500  
 Specialty Interest: general pulmonary medicine



**Jonathon Castro, MD, MS**  
 216.587.8830  
 Specialty Interests: critical care, general pulmonary medicine



**Neal Chaisson, MD**  
 Associate Director, Pulmonary and Critical Care Fellowship Program  
 216.444.7943  
 Specialty Interests: critical care, pulmonary hypertension



**Humberto Choi, MD**  
 216.444.4875  
 Specialty Interests: critical care, lung cancer, advanced diagnostic bronchoscopy



**Chirag Choudhary, MD**  
 Director, MICU, Marymount Hospital Associate Medical Director, ICU Operations, Cleveland Clinic Health System  
 216.444.6090  
 Specialty Interest: critical care



**Joseph Cicienia, MD**  
 216.445.8606  
 Specialty Interests: advanced diagnostic bronchoscopy, lung cancer, pleural disease, COPD



**Stephanie Clough, MD**  
 216.444.6503  
 Specialty Interests: general pulmonary medicine



**Anthony Cucci, MD**  
 330.344.6676  
 Specialty Interests: critical care, general pulmonary medicine



**Daniel Culver, DO**  
 Director, Sarcoidosis and Interstitial Lung Disease Program; Research Officer; Joint Appointment with Pathobiology  
 216.444.6508  
 Specialty Interests: sarcoidosis, interstitial lung disease, hypersensitivity pneumonitis



**Elliott Dasenbrook, MD, MHS**  
 Director, Adult Cystic Fibrosis Program  
 216.445.3082  
 Specialty Interests: cystic fibrosis, non-CF bronchiectasis, nontuberculous microbacterial infection



**Matthew Dettmer, MD**  
 Joint Appointment with Emergency Medicine  
 216.445.8313  
 Specialty Interest: critical care



**Amit Diwakar, MD**  
 330.344.6676  
 Specialty Interests: critical care, general pulmonary medicine



**Sudhir Dudekonda, MD**  
 216.444.7523  
 Specialty Interest: critical care, general pulmonary medicine



**Siddarth Dugar, MD**  
 216.444.7523  
 Specialty Interest: critical care



**Abhijit Duggal, MD, MPH, MS**  
 Associate Director, Critical Care Medicine Fellowship Program  
 216.444.4838  
 Specialty Interest: critical care



**Raed A. Dweik, MD**  
 Director, Pulmonary Vascular Disease Program; Joint Appointment with Pathobiology  
 216.445.5763  
 Specialty Interests: pulmonary hypertension, chronic beryllium disease, critical care, nitric oxide in lung physiology and disease, exhaled markers in lung disease



**Serpil C. Erzurum, MD**  
 Chairman, Lerner Research Institute; Director, Cleveland Clinic General Clinical Research Center; Co-Director, Asthma Center  
 216.445.5764  
 Specialty Interests: asthma, pulmonary vascular disease



**Andrew Garrow, MD**  
 440.312.9636  
 Specialty Interests: critical care, sleep medicine, general pulmonary medicine



**Adi Gerblach, MD**  
 440.312.7140  
 Specialty Interest: critical care



**Thomas R. Gildea, MD, MS**  
 Head, Section of Bronchoscopy  
 216.444.6490  
 Specialty Interests: advanced diagnostic and interventional bronchoscopy, lung cancer, pleural disease



**Namita Gupta, MD**  
 440.312.7140  
 Specialty Interest: critical care



**Jorge Guzman, MD**  
 Chief Medical Officer, Cleveland Clinic Abu Dhabi  
 216.445.5765  
 Specialty Interests: critical care, sepsis, shock



**Tarik Hanane, MD**  
 216.445.2747  
 Specialty Interest: critical care



**Umur Hatipoğlu, MD**  
 Quality Improvement Officer; Director, COPD Program  
 216.636.5344  
 Specialty Interests: COPD, general pulmonary medicine, critical care



**Gustavo Heresi, MD**  
 Medical Director, Pulmonary Thromboendarterectomy Program  
 216.636.5327  
 Specialty Interests: pulmonary hypertension, chronic thromboembolic pulmonary hypertension (CTEPH), acute pulmonary embolism



**Kristin Highland, MD, MS**  
 216.445.5429  
 Specialty Interests: interstitial lung disease, pulmonary manifestations of CVD, pulmonary hypertension



**R. Duncan Hite, MD**  
 Research Director, Department of Critical Care; Joint Appointment with Pathobiology  
 216.445.3099  
 Specialty Interest: critical care



**Lamia Ibrahim, MD**  
 216.445.1701  
 Specialty Interests: critical care, asthma, general pulmonary medicine



**Harish Kakarala, MD**  
 Program Director, Internal Medicine Residency, Akron General  
 330.344.6676  
 Specialty Interests: critical care, general pulmonary medicine, sleep medicine



**Aanchal Kapoor, MD**  
 Associate Director, Critical Care Medicine Fellowship Program  
 216.444.4100  
 Specialty Interest: critical care



**Joseph Khabbaza, MD**  
 216.444.6503  
 Specialty Interests: critical care, general pulmonary medicine



**Safdar Khan, MD**  
 Director, Respiratory Institute West Region  
 216.445.9119  
 Specialty Interests: critical care, general pulmonary medicine



**Sumita Khatri, MD, MS**  
 Co-Director, Asthma Center; Joint Appointment with Pathobiology  
 216.445.1701  
 Specialty Interest: asthma



**Sudhir Krishnan, MD**  
 216.445.2570  
 Specialty Interest: critical care



**Louis Lam, MD**  
 216.444.6503  
 Specialty Interests: general pulmonary medicine, advanced diagnostic bronchoscopy, critical care, lung cancer



**C. Randall Lane, MD**  
 216.444.0586  
 Specialty Interests: lung transplantation, critical care



**Ann Leano, MD**  
 330.344.6676  
 Specialty Interests: critical care, general pulmonary medicine



**Kar-Ming Lo, MD**  
 Joint Appointment with Sleep Center  
 216.292.5750  
 Specialty Interests: critical care, general pulmonary medicine, sleep medicine



**Michael Machuzak, MD**  
 Medical Director, Center for Major Airway Diseases  
 216.444.2718  
 Specialty Interests: advanced diagnostic and interventional bronchoscopy, lung cancer, pleural disease



**Peter Mazzone, MD, MPH**  
 Director, Lung Cancer Program  
 216.445.4812  
 Specialty Interest: lung cancer



**Glenn Meden, MD**  
 Chief, Division of Pulmonary and Critical Care Medicine, Hillcrest Hospital; Director, Respiratory Institute East Region  
 440.312.7140  
 Specialty Interests: general pulmonary medicine, critical care



**Reena Mehra, MD, MS**  
 Joint Appointment with Sleep Center  
 216.444.6967  
 Specialty Interests: general pulmonary medicine, sleep medicine



**Atul C. Mehta, MD**  
 216.444.2911  
 Specialty Interests: lung transplantation, advanced diagnostic bronchoscopy, lung cancer



**Eduardo Mireles-Cabodevila, MD**  
 Director, Critical Care Fellowship Program  
 216.445.2523  
 Specialty Interests: critical care, neuromuscular diseases



**Ajit Moghekar, MD**  
 216.444.6317  
 Specialty Interest: critical care



**Timothy C. Murray, MD**  
 Service Chief, Pulmonary Medicine, Akron General; Medical Director, Sleep Center, Akron General and Stow; Medical Director, Pulmonary Function & Rehabilitation, Akron General  
 330.344.6676  
 Specialty Interests: critical care, general pulmonary medicine, sleep medicine, hyperbaric medicine



**Manuel Ribeiro Neto, MD**  
 216.444.6503  
 Specialty Interests: general pulmonary medicine, sarcoidosis, interstitial lung disease, advanced diagnostic bronchoscopy



**Kathrin Nicolacakis, MD**  
 Director, Medical Compliance, Billing and Reimbursement  
 216.444.0772  
 Specialty Interest: general pulmonary medicine



**Thomas Olbrych, MD**  
 Director, Respiratory Institute Medina-Wooster Region  
 330.721.5700  
 Specialty Interest: general pulmonary medicine



**Mitchell Olman, MD**  
 Joint Appointment with Pathobiology  
 216.445.6025  
 Specialty Interest: interstitial lung disease



**Beverly V. O'Neill, MD**  
 Vice President, Medical Operations, Euclid Hospital  
 216.692.7848  
 Specialty Interests: general pulmonary medicine, critical care



**Aman Pande, MD**  
 440.695.4000  
 Specialty Interests: critical care, general pulmonary medicine, sarcoidosis, interstitial lung disease



**Joseph G. Parambil, MD**  
 Director, Hereditary Hemorrhagic Telangiectasia (HHT) Center  
 216.444.7567  
 Specialty Interests: interstitial lung disease, pulmonary hypertension, HHT, general pulmonary medicine



**Michael A. Passero Jr., MD**  
 Service Chief, Wound Care and Hyperbaric Medicine, Akron General; Medical Director, Sleep Center, Green  
 330.344.6676  
 Specialty Interests: critical care, general pulmonary medicine, hyperbaric medicine



**Bohdan Picurko, MD**  
 Director, Pulmonary Function Lab  
 216.445.6789  
 Specialty Interest: general pulmonary medicine



**Fatima Pozuelo, MD**  
 Medical Director, Respiratory Therapy and Pulmonary Rehabilitation, Hillcrest Hospital  
 440.312.7140  
 Specialty Interest: general pulmonary medicine



**Robier Aguillon Prada, MD**  
 440.312.7140  
 Specialty Interest: critical care



**Hardeep Rai, MD**  
 Medical Director, Respiratory Therapy and Pulmonary Rehabilitation, Medina Hospital  
 330.721.5700  
 Specialty Interests: general pulmonary medicine, critical care



**Prabalini Rajendram, MD**  
 216.476.7983  
 Specialty Interest: critical care



**Jennifer Ramsey, MD, MS**  
 Joint Appointment with Palliative Medicine  
 216.445.8407  
 Specialty Interest: critical care



**Deborah Rathz, MD, PhD**  
 Joint Appointment with Emergency Medicine  
 216.445.8318  
 Specialty Interest: critical care



**Muhammad Raza, MD, MBA**  
 Director, MICU, Fairview Hospital  
 216.445.9119  
 Specialty Interests: general pulmonary medicine, critical care



**Anita Reddy, MD**  
 Quality Officer, Medical Intensive Care Unit  
 216.444.4506  
 Specialty Interests: critical care, acute lung injury



**Debasis Sahoo, MD**  
 216.444.5978  
 Specialty Interests: general pulmonary medicine, sarcoidosis, interstitial lung disease, critical care



**Raymond Salomone, MD**  
 216.639.0448  
 Specialty Interests: critical care, general pulmonary medicine



**Madhu Sasidhar, MD**  
 Head, Section of Respiratory Therapy  
 216.445.1838  
 Specialty Interest: critical care



**Rachel Scheraga, MD**  
 Joint Appointment with Pathobiology  
 216.444.4429  
 Specialty Interest: critical care



**Sonali Sethi, MD**  
 216.445.1631  
 Specialty Interests: advanced diagnostic and interventional bronchoscopy, lung cancer, pleural disease



**David Skirball, MD**  
 440.639.0448  
 Specialty Interests: critical care, general pulmonary medicine



**Andre Smith, MD**  
 440.312.7140  
 Specialty Interest: general pulmonary medicine



**Brian Southern, MD**  
 216.444.7655  
 Joint Appointment with Pathobiology  
 Specialty Interest: interstitial lung disease



**Leah Spinner, MD**  
 440.312.7140  
 Specialty Interests: critical care, general pulmonary medicine



**James K. Stoller, MD, MS**  
 Chairman, Education Institute  
 216.444.1960  
 Specialty Interests: clinical epidemiology, alpha-1 antitrypsin deficiency, respiratory therapy



**Anu Suri, MD**  
 Section Chief, Pulmonary Medicine, Avon Hospital  
 216.476.7983  
 Specialty Interests: critical care, general pulmonary medicine, advance directives



**Rachel Taliercio, DO**  
 216.445.1701  
 Specialty Interests: general pulmonary medicine, asthma



**Sanjiv Tewari, MD**  
 Director, Respiratory Institute, Akron Region; Chairman, Department of Medicine, Akron General  
 330.344.6676  
 Specialty Interests: critical care, neuro critical care, general pulmonary medicine, sleep medicine, advanced bronchoscopy



**Leslie Tolle, MD**  
 216.444.4882  
 Specialty Interests: critical care, interstitial lung disease, general pulmonary medicine



**Adriano Tonelli, MD, MSc**  
 216.444.0812  
 Specialty Interest: pulmonary hypertension



**Wayne Tsuang, MD, MHS**  
 216.445.6448  
 Specialty Interests: critical care, lung transplantation



**Jason Turowski, MD**  
 216.445.7098  
 Specialty Interests: lung transplantation, critical care, cystic fibrosis



**Maryam Valapour, MD, MPP**  
 Director, Lung Transplant Outcomes  
 216.445.4071  
 Specialty Interest: lung transplantation



**Lokesh Venkateshaiah, MD**  
 Service Chief, Critical Care, Akron General  
 330.344.6676  
 Specialty Interests: critical care, general pulmonary medicine



**Joe Zein, MD**  
 216.839.3820  
 Specialty Interests: critical care, general pulmonary medicine, asthma

**Department of Allergy and Clinical Immunology**



**David M. Lang, MD**  
 Chairman, Department of Allergy and Clinical Immunology; Director, Allergy Fellowship Program; Co-Director, Asthma Center  
 216.445.5810  
 Specialty Interests: asthma, allergic disorders, sinusitis, urticaria, anaphylaxis, drug desensitization, aspirin sensitivity



**Sheila Armogida, MD**  
 330.721.5700  
 Specialty Interests: allergic disorders, asthma



**Mark A. Aronica, MD**  
 Joint Appointment with Pathobiology  
 216.444.6933  
 Specialty Interests: asthma, allergic disorders



**Bela Faltay, MD**  
 Chief, Allergy Services, Akron General  
 330.252.9310  
 Specialty Interests: allergic disorders, asthma



**James Fernandez, MD, PhD**  
 216.445.8573  
 Specialty Interests: allergic disorders, clinical immunology, immune deficiency



**Sandra Hong, MD**  
 440.878.2500  
 Specialty Interests: allergic disorders, asthma



**Fred H. Hsieh, MD**  
 Joint Appointment with Pathobiology  
 216.444.3504  
 Specialty Interests: asthma, allergic disorders, mast cell disorders



**Lily C. Pien, MD, MHPE**  
 216.444.6933  
 Specialty Interests: allergic rhinitis, asthma, drug allergies, latex allergy, medical education



**Ronald Purcell, MD**  
 216.444.6503  
 Specialty Interests: allergic disorders, asthma



**Roxana Siles, MD**  
 216.444.6933  
 Specialty Interests: allergic disorders, asthma



**Ahila Subramanian, MD, MPH**  
 216.444.6933  
 Specialty Interests: allergic disorders, asthma



**Marta Vielhaber, MD**  
 216.444.6503  
 Specialty Interests: allergic disorders, asthma



**Li Zuo, MD**  
 440.204.7400  
 Specialty Interests: allergic disorders, asthma

**CLEVELAND CLINIC FLORIDA RESPIRATORY CENTER**

**Cleveland Clinic Florida Pulmonary & Critical Care Medicine**



**Franck Rahaghi, MD, MHS**  
 Chairman, Cleveland Clinic Florida Pulmonary and Critical Care Medicine  
 954.659.5000  
 Specialty Interests: critical care, asthma, general pulmonary medicine, pulmonary hypertension



**Sajjive Aleyas, MD**  
 954.659.5000  
 Specialty Interests: advanced diagnostic bronchoscopy, lung cancer, critical care, general pulmonary medicine



**Sam Faradyan, MD**  
 954.659.5000  
 Specialty Interests: critical care, asthma, general pulmonary medicine



**Sam Gurevich, MD**  
 Medical Director, Respiratory Therapy  
 954.659.5000  
 Specialty Interests: critical care, general pulmonary medicine



**Anas Hadeh, MD**  
 954.659.5000  
 Specialty Interests: critical care, asthma, general pulmonary medicine



**Nydia Martinez, MD**  
 954.659.5000  
 Specialty Interests: critical care, asthma, general pulmonary medicine



**Jinesh Mehta, MD**  
 954.659.5000  
 Specialty Interests: critical care, asthma, general pulmonary medicine



**Laurence Smolley, MD**  
 Medical Director, Cleveland Clinic Florida Sleep Center  
 954.659.5000  
 Specialty Interests: critical care, general pulmonary medicine, sleep medicine

**Cleveland Clinic Florida Allergy & Clinical Immunology**



**Frank Eidelman, MD**  
 Chairman, Department of Allergy and Immunology  
 954.659.5813  
 Specialty Interests: allergic disorders, asthma



**Vesselin Dimov, MD**  
 954.659.5813  
 Specialty Interests: allergic disorders, asthma

**PARTNERS IN OTHER DEPARTMENTS**

**Diagnostic Radiology Section of Thoracic Imaging**



**Ruffin J. Graham, MD**  
 Head, Section of Thoracic Imaging  
 216.444.8756  
 Specialty Interests: pulmonary thromboembolism, lung cancer and thromboembolic disease



**Joseph Azok, MD**  
 216.444.0282  
 Specialty Interest: thoracic imaging



**Ryo Benson, MD**  
 216.636.5442  
 Specialty Interest: thoracic imaging



**Michael Bolen, MD**  
 216.636.6168  
 Specialty Interest: thoracic imaging



**Subha Ghosh, MD**  
 216.444.1014  
 Specialty Interest: thoracic imaging



**Omar Lababede, MD**  
 216.444.9014  
 Specialty Interest: thoracic imaging



**Jason Lempel, MD**  
 216.636.2500  
 Specialty Interest: thoracic imaging



**Rahul Renapurkar, MD**  
 216.445.7050  
 Specialty Interest: thoracic imaging



**Barbara Risius, MD**  
 216.444.6422  
 Specialty Interest: thoracic radiology



**Ruchi Yadav, MD**  
 216.445.7050  
 Specialty Interest: thoracic imaging

**Pulmonary Pathology**



**Carol F. Farver, MD**  
 Director, Pulmonary Pathology  
 216.445.7695  
 Specialty Interest: pulmonary pathology



**Andrea Arrossi, MD**  
 Joint Appointment with Pulmonary  
 216.444.9120  
 Specialty Interest: pulmonary pathology



**Sanjay Mukhopadhyay, MD**  
 216.444.5893  
 Specialty Interest: pulmonary pathology

**Thoracic and Cardiovascular Surgery**



**Usman Ahmad, MD**  
 216.444.1921  
 Specialty Interest: thoracic oncology, general thoracic surgery, lung transplantation



**Douglas Johnston, MD**  
 216.444.5613  
 Specialty Interest: lung and heart transplantation



**Kenneth McCurry, MD**  
 Surgical Director, Lung Transplantation; Joint Appointment with Pathobiology  
 216.445.9303  
 Specialty Interests: lung and heart transplantation, ventricular assist devices, heart failure surgery, lung and heart ischemia-reperfusion injury



**Michael Zhen-Yu Tong, MD, MBA**  
 216.445.0807  
 Specialty Interest: lung and heart transplantation

**Section of General Thoracic Surgery**



**Sudish Murthy, MD, PhD**  
 Head, Section of General Thoracic Surgery  
 216.444.5640  
 Specialty Interests: esophageal, pulmonary, mediastinal, chest wall and diaphragm surgery; minimally invasive lung volume reduction surgery; lung transplant surgery



**Siva Raja, MD, PhD**  
 216.445.6860  
 Specialty Interests: lung cancer, esophageal cancer



**Daniel Raymond, MD**  
 216.636.1623  
 Specialty Interests: general thoracic surgery, lung cancer

**RESOURCES FOR PHYSICIANS**

**Stay Connected with Cleveland Clinic's Respiratory Institute**

**Consult QD**

A blog featuring insights and perspectives from Cleveland Clinic experts. Visit today and join the conversation.

[consultqd.clevelandclinic.org](http://consultqd.clevelandclinic.org)



**Facebook for Medical Professionals**  
 Facebook.com/CMEClevelandClinic



**Follow us on Twitter**  
 @CleClinicMD



**Connect with us on LinkedIn**  
[clevelandclinic.org/MDlinkedin](http://clevelandclinic.org/MDlinkedin)



**On the web at**  
[clevelandclinic.org/respiratory](http://clevelandclinic.org/respiratory)

**24/7 Referrals**

**Referring Physician Center and Hotline**  
 855.REFER.123 (855.733.3712)

[clevelandclinic.org/Refer123](http://clevelandclinic.org/Refer123)

Live help connecting with our specialists, scheduling and confirming appointments, and resolving service-related issues.



**Physician Referral App**  
 Download today at the App Store or Google Play.

**Physician Directory**  
[clevelandclinic.org/staff](http://clevelandclinic.org/staff)

**Same-Day Appointments**

To help your patients get the care they need, right away, have them call our same-day appointment line, 216.444.CARE (2273) or 800.223.CARE (2273).

**Track Your Patients' Care Online**

Establish a secure online DrConnect account at [clevelandclinic.org/drconnect](http://clevelandclinic.org/drconnect) for real-time information about your patients' treatment.

**Critical Care Transport Worldwide**

To arrange for a critical care transfer, call 216.448.7000 or 866.547.1467. [clevelandclinic.org/criticalcaretransport](http://clevelandclinic.org/criticalcaretransport)

**Outcomes Data**

View Outcomes books at [clevelandclinic.org/outcomes](http://clevelandclinic.org/outcomes).

**CME Opportunities**

Visit [ccfcm.org](http://ccfcm.org) for convenient learning opportunities from Cleveland Clinic's Center for Continuing Education.

**Executive Education**

Learn about our Executive Visitors' Program and two-week Samson Global Leadership Academy immersion program at [clevelandclinic.org/executiveeducation](http://clevelandclinic.org/executiveeducation).



**The Cleveland Clinic Way Book Series**

Lessons in excellence from one of the world's leading healthcare organizations:

*The Cleveland Clinic Way*  
 Toby Cosgrove, MD, CEO and President, Cleveland Clinic

*Communication the Cleveland Clinic Way*  
 Adrienne Boissy, MD, MA, and Tim Milligan, MD, MS

*Innovation the Cleveland Clinic Way*  
 Thomas J. Graham, MD, Former Chief Innovation Officer, Cleveland Clinic

*Service Fanatics*  
 James Merlino, MD, Former Chief Experience Officer, Cleveland Clinic

*IT's About Patient Care: Transforming Healthcare Information Technology the Cleveland Clinic Way*  
 By C. Martin Harris, MD

Visit [clevelandclinic.org/ClevelandClinicWay](http://clevelandclinic.org/ClevelandClinicWay) for details or to order a copy.



The Cleveland Clinic Foundation  
Respiratory Institute / AC311  
9500 Euclid Ave.  
Cleveland, OH 44195

RESPIRATORY EXCHANGE  RESEARCH AND NEWS FOR PHYSICIANS FROM  
CLEVELAND CLINIC'S RESPIRATORY INSTITUTE



## Consult QD

### PHYSICIAN BLOG

A blog featuring insights and perspectives from Cleveland Clinic experts. Visit today and join the conversation.

[consultqd.clevelandclinic.org/pulmonary](http://consultqd.clevelandclinic.org/pulmonary)



